1
|
Cesarone MR, Belcaro G, Cox D, Scipione V, Scipione C, Dugall M, Cornelli U, Hosoi M, Feragalli B, Hu S, Cotellese R. Pycnogenol® prevents skin hyperpigmentation following sclerotherapy. Minerva Surg 2024; 79:161-165. [PMID: 38592434 DOI: 10.23736/s2724-5691.23.10035-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/10/2024]
Abstract
BACKGROUND The aim of this registry supplement study was to evaluate the effects of the oral supplement Pycnogenol® on possible skin discolorations or other minor skin changes after varicose vein sclerotherapy in comparison with a standard management (SM). METHODS One hundred sixty-one subjects completed the study. 84 took Pycnogenol® from the day before sclerotherapy for 12 weeks and followed SM. 77 followed SM only and served as controls. 420 injection sites were followed-up in the Pycnogenol® group and 431 in the control group. The number of injected veins (using only Aetoxysklerol) was on average 4-8 veins/patient. No side effects were observed for the SM or for supplementation. Pycnogenol® supplementation showed a good tolerability. The two management groups were comparable for age, sex and veins distribution at inclusion. RESULTS After 12 weeks, skin discoloration assessed by a skin staining score was generally significantly lower and less frequent (P<0.05) with Pycnogenol® with a score of 0.4±0.2 compared to controls (with a score of 2.1±0.4). In addition, the number of stains per treated vein was significantly lower in the Pycnogenol® group than the control group. CONCLUSIONS Varicose vein sclerotherapy is a minimally invasive procedure almost without complications. Pycnogenol® intake appears to improve healing and prevent skin discolorations after injection of the sclerosing agent. To verify this effect of Pycnogenol®, more studies for a longer period are needed.
Collapse
Affiliation(s)
| | - Gianni Belcaro
- Irvine3 labs & PAP/PEA Screening Project, Pescara, Italy -
| | - David Cox
- Irvine3 labs & PAP/PEA Screening Project, Pescara, Italy
| | | | | | - Mark Dugall
- Irvine3 labs & PAP/PEA Screening Project, Pescara, Italy
| | | | - Morio Hosoi
- Irvine3 labs & PAP/PEA Screening Project, Pescara, Italy
| | - Beatrice Feragalli
- Irvine3 labs & PAP/PEA Screening Project, Pescara, Italy
- Department of Medical, Oral and Biotechnological Sciences, Chieti, Italy
| | - Shu Hu
- Irvine3 labs & PAP/PEA Screening Project, Pescara, Italy
| | - Roberto Cotellese
- Irvine3 labs & PAP/PEA Screening Project, Pescara, Italy
- Department of Medical, Oral and Biotechnological Sciences, Chieti, Italy
| |
Collapse
|
2
|
Cesarone MR, Hu S, Belcaro G, Cornelli U, Feragalli B, Corsi M, Scipione V, Scipione C, Cotellese R, Hosoi M, Cox D. Borderline hyperlipidemia preventive management with Berberine PL in asymptomatic prevention of early atherosclerosis. Minerva Gastroenterol (Torino) 2024; 70:10-15. [PMID: 37856087 DOI: 10.23736/s2724-5985.23.03540-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2023]
Abstract
BACKGROUND The aim of this pilot, efficacy supplement registry was to use a supplementary management with berberine to control hyperlipidemia. The supplement Berberine (Berbevis™ as Sophy® tablets) was used to control lipids and to evaluate (as a natural, preventive management) the early evolution of subclinical atherosclerosis in subjects (otherwise healthy, not using drugs) with borderline hyperlipidemia. METHODS The registry involved two groups of subjects not using drugs for a total of 50 subjects and three months of supplementation. RESULTS The registry groups using standard management (SM) or SM and supplement were resulted comparable. No side effects were observed during the three months of berberine supplementation. No tolerability problems were reported. All subjects managed with berberine completed the three-month registry. Compliance was >97% (% of correctly used tablets). Total cholesterol was significantly decreased with berberine (P<0.05) and HDL was significantly improved (P<0.5) with supplementation. Triglycerides decreased in the berberine groups (P<0.05) and the levels of CoQ10 remained within normal values in supplemented subjects. Oxidative stress - measured in Carr units - was significantly decreased with berberine (P<0.05). Routine blood tests remained within normal values during the registry. Body weight was significantly more decreased (P<0.05) with berberine in comparison with standard management. The fat proportion also decreased (P<0.05) with berberine supplementation and the abdominal fat thickness (in the peri-umbilical area) was significantly decreased after berberine supplementation (P<0.05). CONCLUSIONS This pilot registry indicates that berberine administration is effective in reducing lipids (decreasing weight, fat percentage and abdominal fat) in otherwise healthy subjects not using drugs. A longer study, with more advanced hyperlipidemic subjects is suggested. Predictive analytics according to Siegel suggests that a six-month study with 60 patients, in more advanced hyperlipidemic, also evaluating the intima-media thickness for the analysis of vascular benefits, may produce a stronger evaluation for this product.
Collapse
Affiliation(s)
| | - Shu Hu
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy
| | - Gianni Belcaro
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy -
| | | | - Beatrice Feragalli
- Department of Or Biotec Sciences, Chieti-Pescara University, Chieti, Italy
| | | | | | | | - Roberto Cotellese
- Department of Or Biotec Sciences, Chieti-Pescara University, Chieti, Italy
| | - Morio Hosoi
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy
| | - David Cox
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy
| |
Collapse
|
3
|
Belcaro G, Cornelli U, Cox D, Dugall M, Cesarone MR, Ledda A, Scipione V, Scipione C, Feragalli B, Cotellese R. Intestinal fat absorption shifting by polyglucosamine biopolymer: control of lipids and reduction of progression of early subclinical atherosclerosis. Minerva Gastroenterol (Torino) 2024; 70:22-28. [PMID: 37943250 DOI: 10.23736/s2724-5985.23.03539-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/10/2023]
Abstract
BACKGROUND Atherosclerosis progression is possible in subjects with limited alteration of body weight, lipid profile, and oxidative stress. The ultrasound carotid thickness (IMT) and arterial wall modification (granulation and bubbles) are evident signs of the disease. Intestinal fats absorption shifting (IFAS) is expected to prevent or reduce the arterial damage. The aim of the registry was to evaluate the effects of a mild diet in association with lifestyle modifications (standard management [SM]) and SM+ a polyglucosamine biopolymer (BP) shifting the intestinal absorption of dietary fats. METHODS The present is a two-year registry comparing two groups of otherwise healthy subjects, respectively 150 (SM) and 144 (SM+BP). BP was administered at the dosage of 3g/day. IMT and relative arterial damages were measured together with lipid profile, oxidative stress, anthropometric and vital measures. RESULTS The two groups at the baseline were comparable for all variables: 8 cases of drop out were found limited to SM. Compliance with BP was optimal (>97%) and no side effect were observed. IMT showed a significant decrease in thickness (P<0.05) using BP+SM, while increased in SM group. Intimal granulations and lipid wall bubbles were also significantly decreased with BP in comparison to SM only (P<0.05). BMI significantly decreased with BP (P<0.05) as well as BW, fat mass, lipid profile and oxidative stress in comparison to SM only. A positive variation in blood pressure and heart rate (P<0.05) was also observed. CONCLUSIONS BP allows IFAS to improve early subclinical arterial lesions that tend to progress to plaques and clinical events. The long-term and safe treatment of BP is effective on IMT, lipids, BW, and early lesions of the arterial wall structure in subjects with subclinical conditions. BP also reduces oxidative stress which contributes to lipid oxidation and deposition into the arterial wall layer in areas of high dynamic stress (arterial bifurcations).
Collapse
Affiliation(s)
- Gianni Belcaro
- Irvine3 Institute and International Agency for Pharma-Standard Supplements, Pescara, Italy -
| | | | - David Cox
- Irvine3 Institute and International Agency for Pharma-Standard Supplements, Pescara, Italy
| | - Mark Dugall
- Irvine3 Institute and International Agency for Pharma-Standard Supplements, Pescara, Italy
| | - Maria R Cesarone
- Irvine3 Institute and International Agency for Pharma-Standard Supplements, Pescara, Italy
| | - Andrea Ledda
- Irvine3 Institute and International Agency for Pharma-Standard Supplements, Pescara, Italy
| | - Valeria Scipione
- Irvine3 Institute and International Agency for Pharma-Standard Supplements, Pescara, Italy
| | - Claudia Scipione
- Irvine3 Institute and International Agency for Pharma-Standard Supplements, Pescara, Italy
| | | | | |
Collapse
|
4
|
Cesarone MR, Belcaro G, Scipione C, Scipione V, Dugall M, Hu S, Feragalli B, Cotellese R. Xerostomia and prevention of dryness with a Pycnogenol® mouth spray: a pilot study. Minerva Gastroenterol (Torino) 2024; 70:36-41. [PMID: 37162467 DOI: 10.23736/s2724-5985.22.03245-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
BACKGROUND The aim of this pilot, supplement study was the evaluation of primary, idiopathic mucosal mouth dryness (xerostomia or dry mouth) in subjects without systemic diseases. METHODS Subjects with xerostomia were managed either with standard management (SM) or with SM and a Pycnogenol® mouth spray (Hankintatukku Oy, Karkkila, Finland), at the dosage of 60 mg/day in 30 spurts, for 2 weeks. RESULTS A total of 50 subjects were included in the study: 25 controls using only standard management (SM) and 25 subjects using the Pycnogenol® mouth spray. No side effects and no tolerability problems were observed with the Pycnogenol® mouth spray. The groups were comparable for characteristics and symptoms at baseline. These otherwise healthy subjects had a BMI<26. After 2 weeks, salivary flow and salivary oxidative stress (in Carr Units) were improved significantly with Pycnogenol® mouth spray as compared to controls (P<0.05), whereas minimal improvements in salivary flow were seen with SM. The subjective symptomatic dry mouth score and the number of mucosal breaks and ulcerations (all minimal, <1 mm in length or diameter) were significantly decreased with the Pycnogenol® mouth spray supplement compared to SM controls (P<0.05). The Pycnogenol® mouth spray led to significant improvement in salivary lysozyme levels, compared to controls (P<0.05). CONCLUSIONS Based on these preliminary results, Pycnogenol® mouth spray could be a new supplementary option for the management of primary xerostomia.
Collapse
Affiliation(s)
- Maria R Cesarone
- Irvine3 Labs, San Valentino Vascular Screening Project, and International Agency for Pharma-Standard Supplements (IA-PSS), Pescara, Italy
| | - Gianni Belcaro
- Irvine3 Labs, San Valentino Vascular Screening Project, and International Agency for Pharma-Standard Supplements (IA-PSS), Pescara, Italy -
| | - Claudia Scipione
- Irvine3 Labs, San Valentino Vascular Screening Project, and International Agency for Pharma-Standard Supplements (IA-PSS), Pescara, Italy
| | - Valeria Scipione
- Irvine3 Labs, San Valentino Vascular Screening Project, and International Agency for Pharma-Standard Supplements (IA-PSS), Pescara, Italy
| | - Mark Dugall
- Irvine3 Labs, San Valentino Vascular Screening Project, and International Agency for Pharma-Standard Supplements (IA-PSS), Pescara, Italy
| | - Shu Hu
- Irvine3 Labs, San Valentino Vascular Screening Project, and International Agency for Pharma-Standard Supplements (IA-PSS), Pescara, Italy
| | | | - Roberto Cotellese
- DSMO-Biotec, Pescara, Italy
- School of General Surgery, Department of Outpatients Vascular Surgery, Chieti-Pescara University, Pescara, Italy
| |
Collapse
|
5
|
Belcaro G, Cesarone MR, Scipione C, Scipione V, Hosoi M, Hu S, Ledda A, Feragalli B, Cotellese R, Cox D. Periostial and cartilage morphology in knee osteoarthritis: beneficial effects of supplementation with Pycnogenol® + Centellicum®. Minerva Surg 2024; 79:40-47. [PMID: 38381030 DOI: 10.23736/s2724-5691.23.09967-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2024]
Abstract
BACKGROUND The aim of this registry study was to evaluate the progress of osteoarthrosis (OA) symptoms after the intake of a new standardized supplement combination (Pycnogenol® + Centellicum®, both Horphag Research) in a group of subjects with OA. METHODS Supplemented subjects took daily 150 mg Pycnogenol® + 450 mg Centellicum® for 6 months. Another comparable group of subjects using only standard management (SM) was included as a reference. RESULTS Forty-five subjects with a mean age of 42 years completed the study, 25 in the supplemented group and 20 in the SM group. There were no safety problems or tolerability issues with the supplements. The two groups, SM and SM + Pycnogenol® + Centellicum® were comparable for age and clinical characteristics at inclusion. The two main ultrasound characteristics of cartilage, its thickness and surface-irregularity were more improved with the supplements. Pain scores, C reactive protein, the level of fitness and the use of extra pain killers (as rescue medication) were all significantly improved at 6 months with the supplement combination compared to SM (P<0.05). Plasma free radicals, pain-free walking distance on treadmill and erythrocyte sedimentation rate (ESR) were significantly improved with the supplements compared to SM. CONCLUSIONS The morphological improvement - visible with ultrasound - correlates with a decrease in clinical symptoms and with a more efficient ambulation without pain. SM along with the Pycnogenol® Centellicum® combination are useful to avoid drug treatments that may expose patients to some side effects over time.
Collapse
Affiliation(s)
| | | | | | | | | | - Shu Hu
- Irvine3 Labs, Pescara, Italy
| | | | - Beatrice Feragalli
- Department of Medicine, Oral and Biotechnological Sciences, G. D'Annunzio Chieti-Pescara University, Pescara, Italy
| | - Roberto Cotellese
- Department of Medicine, Oral and Biotechnological Sciences, G. D'Annunzio Chieti-Pescara University, Pescara, Italy
| | | |
Collapse
|
6
|
Belcaro G, Cesarone MR, Ledda A, Scipione C, Scipione V, Corsi M, Cox D, Cotellese R, Feragalli B. Altitude trekking and Robuvit®: fatigue prevention and recovery. Minerva Med 2024; 115:83-84. [PMID: 37534833 DOI: 10.23736/s0026-4806.23.08677-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/04/2023]
Affiliation(s)
| | | | | | | | | | | | - David Cox
- Irvine3 Labs Institute, Pescara, Italy
| | - Roberto Cotellese
- Department of Medical, Oral and Biotechnological Sciences, D'Annunzio University Pescara-Chieti, Chieti, Italy
| | - Beatrice Feragalli
- Department of Medical, Oral and Biotechnological Sciences, D'Annunzio University Pescara-Chieti, Chieti, Italy
| |
Collapse
|
7
|
Belcaro G, Hu S, Hosoi M, Cesarone MR, Ledda A, Dugall M, Cornelli U, Saggino A, Cotellese R, Feragalli B, Cox D, Peterzan P, Scipione C, Scipione V. Prevention and control of jet lag symptoms and temporary impairment of cognitive function with Pycnogenol® in healthy individuals and in hypertensives. Minerva Med 2024:S0026-4806.23.08974-7. [PMID: 38197571 DOI: 10.23736/s0026-4806.23.08974-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2024]
Abstract
BACKGROUND The aim of this registry study was to evaluate the efficacy of Pycnogenol® in controlling signs/symptoms and temporary impairment of cognitive function (COFU) associated with jet lag. Previous flight studies have shown a decrease in the level of jet lag symptoms with Pycnogenol®. The control of jet lag signs/symptoms appeared to be correlated with flight-related microangiopathy and peripheral edema. Pycnogenol® - a standardized extract from the bark of French maritime pine - has significant antiedema, anti-inflammatory and antioxidant properties. METHODS A group of subjects flying east in economy class for 10-12 hours used Pycnogenol® 150 mg/day and a similar group without supplementation served as controls. A subgroup of mild hypertensive subjects using a single ACE inhibitor was also included. RESULTS One hundred twenty-seven subjects completed the study. Of the participants, 48 were aviation professionals like pilots, flight attendants or air company staff - 24 of them took Pycnogenol® and 24 served as controls. Forty-seven study participants were frequent flyers and non-staff professionals, 25 of which took Pycnogenol® and 22 served as controls. In addition, a group of 32 subjects with mild hypertension was included, 16 took Pycnogenol® and 16 served as controls. No side effects and a good tolerability were observed. The registry groups were comparable for baseline characteristics. Eastbound flights' duration was 11.22±0.4 hours in supplemented subjects and 11.14±0.32 in controls. Dropouts were due to logistical problems. Post flight Visual Analogue Scale (VAS) scores were significantly lower in all Pycnogenol® groups, including hypertensives for all signs and symptoms of jet lag compared to controls, showing prevention and improvement of jet lag symptoms. The duration of any sign/symptom of jet lag with Pycnogenol® intake was significantly shorter (P<0.05) post-flight compared to controls (P<0.05). The number of nights of altered/disturbed sleep was also lower in the Pycnogenol® groups compared to controls. Leg edema was present in almost all subjects with different degrees especially in the hypertensive group. The increase in ankle circumference before and after flight was significantly lower with Pycnogenol® compared to controls (P<0.05). After the flight, average scores of the single COFU tasks were significantly higher in the Pycnogenol® groups compared to controls, showing preserved cognitive function. CONCLUSIONS In conclusion, in this registry study Pycnogenol® was effective in preventing jet lag-related symptoms and preserving cognitive functions without tolerability problems. These observations should be tested in a larger group of subjects including complex individuals prone to edema (i.e. diabetics, hypertensive or older patients).
Collapse
Affiliation(s)
| | - Shu Hu
- Department of Psychology, G. D'Annunzio University, Chieti, Italy
| | - Morio Hosoi
- Irvine3 Circulation/Vascular Labs, Pescara, Italy
| | | | - Andrea Ledda
- Irvine3 Circulation/Vascular Labs, Pescara, Italy
| | - Mark Dugall
- Irvine3 Circulation/Vascular Labs, Pescara, Italy
| | | | - Aristide Saggino
- Department of Psychology, G. D'Annunzio University, Chieti, Italy
| | - Roberto Cotellese
- Department of Medical, Oral and Biotechnological Sciences, G. D'Annunzio University, Pescara, Italy
| | - Beatrice Feragalli
- Department of Medical, Oral and Biotechnological Sciences, G. D'Annunzio University, Pescara, Italy
| | - David Cox
- Irvine3 Circulation/Vascular Labs, Pescara, Italy
| | | | | | | |
Collapse
|
8
|
Belcaro G, Dugall M, Hosoi M, Ippolito E, Cesarone MR, Cox D, Scipione C, Scipione V, Cornelli U, Corsi M, Feragalli B, Cotellese R. Positive effects of Pycnogenol®-Centellicum® on venous elasticity: an ex-vivo concept study. Minerva Surg 2023; 78:651-656. [PMID: 37534931 DOI: 10.23736/s2724-5691.23.09935-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/04/2023]
Abstract
BACKGROUND The aim of this ex-vivo study was to evaluate the efficacy of Pycnogenol®-Centellicum® oral supplementation on vein segments, retrieved from graft harvesting or from vein surgery. The parameters assessed were elasticity and recovery after dynamic tests: 1) an enlargement stress; 2) an elongation stress; and 3) elasticity after torsion. The tests were made in standardized conditions, less than 3 hours after explant, at 22 °C by the same operator with surgical and microsurgical experience. METHODS Veins of 59 subjects were included in the study: 17 subjects with normal veins with a planned bypass graft and 42 subjects with varicose veins. Of the subjects with normal veins, 8 subjects followed standard management (group 1) and 9 took Pycnogenol®-Centellicum® for 4 weeks before surgery (group 2). In the group with varicose veins, 22 subjects served as controls (group 3) and 20 were supplemented with Pycnogenol®-Centellicum® for 4 weeks before surgery (group 4). No side effects or tolerability problems were observed in the supplementation period before surgery and veins harvesting. The full return to initial shape/sizes after dynamic stress was evaluated in 1 min after removing the stress. RESULTS In group 1, 4 out of 8 vein segments recovered their size after forced enlargement vs. 7/9 in the Pycnogenol®-Centellicum® group 2 (P<0.05). In the elongation test, 3/8 normal control vein segments recovered their length (group 1) vs. 7/9 in the supplement group (group 2) (P<0.05). In the torsion test, 4/8 (group 1) veins recovered their shape after torsion vs. 9/9 veins in Pycnogenol®-Centellicum®-pretreated segments (group 2) (P<0.05). Only 45.8% of normal, control vein segments (group 1) recovered their shape/size in comparison with 85.2% of normal vein segments in the supplement group (group 2) (P<0.05). In group 3 and 4 (segments of varicose veins), the proportion of vein segments with enlargements, elongation and torsion were significantly lower at the end of the test (P<0.05) in the Pycnogenol®-Centellicum® group 4 with 51.7% of the vein segments recovering their shape in the Pycnogenol®-Centellicum® vs. 16.6% of the vein segments recovering their shape in control segments (P<0.05). Results show that Pycnogenol®-Centellicum® supplementation allows vein segments to better return to their original shape/size after a morphological alteration of shape (in different directions). This could be an expression of an improved wall tone and elasticity of the veins. No vein was teared or damaged during the 59 tests indicating that all stresses were well within the normal wall tensile characteristics of the veins. CONCLUSIONS In this study, Pycnogenol®-Centellicum® improved vein elasticity in subjects with normal and varicose veins as vein segments were more elastic (able to recover length and shape) and less passively dilated by high pressure or dynamic stresses. This study indicates that the protective effects of Pycnogenol®-Centellicum® may partially stop passive dilatation of veins to varicose veins over time by improving vein elasticity. Pycnogenol®-Centellicum® managed vein segments return more rapidly back to the initial dimensions, shapes and diameters after a dynamic stress.
Collapse
Affiliation(s)
- Gianni Belcaro
- Irvine3 Circulation Sciences, G. D'Annunzio University, Pescara, Italy -
| | - Mark Dugall
- Irvine3 Circulation Sciences, G. D'Annunzio University, Pescara, Italy
- Department of Vascular Surgery, University of Milan, Milan, Italy
- Oolex, Pescara, Italy
| | - Morio Hosoi
- Irvine3 Circulation Sciences, G. D'Annunzio University, Pescara, Italy
- Department of Vascular Surgery, University of Milan, Milan, Italy
- Oolex, Pescara, Italy
| | - Edmondo Ippolito
- Department of Vascular Surgery, University of Milan, Milan, Italy
| | - Maria R Cesarone
- Irvine3 Circulation Sciences, G. D'Annunzio University, Pescara, Italy
| | - David Cox
- Irvine3 Circulation Sciences, G. D'Annunzio University, Pescara, Italy
- Department of Vascular Surgery, University of Milan, Milan, Italy
- Oolex, Pescara, Italy
| | - Claudia Scipione
- Irvine3 Circulation Sciences, G. D'Annunzio University, Pescara, Italy
| | - Valeria Scipione
- Irvine3 Circulation Sciences, G. D'Annunzio University, Pescara, Italy
| | - Umberto Cornelli
- Irvine3 Circulation Sciences, G. D'Annunzio University, Pescara, Italy
| | - Marcello Corsi
- Irvine3 Circulation Sciences, G. D'Annunzio University, Pescara, Italy
| | | | - Roberto Cotellese
- Specialization School in General Surgery, G. D'Annunzio University, Pescara, Italy
| |
Collapse
|
9
|
Belcaro G, Cesarone MR, Scipione C, Scipione V, Cox D, Cornelli U, Cotellese R, Dugall M, Hosoi M, Corsi M, Feragalli B. Chronic venous insufficiency (CVI) in diabetics: supplementation with Pycnogenol®+Centellicum® prevents edema and the evolution of microangiopathy. Minerva Med 2023; 114:881-883. [PMID: 37382514 DOI: 10.23736/s0026-4806.23.08703-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/30/2023]
Affiliation(s)
- Giovanni Belcaro
- IRVINE3 and Nicolaides Labs, Circulation Sciences and San Valentino, Vascular Screening Project, Pescara, Italy -
- International Agency for Pharma Standard Supplements (IAPPS), Pescara, Italy -
| | - Maria R Cesarone
- IRVINE3 and Nicolaides Labs, Circulation Sciences and San Valentino, Vascular Screening Project, Pescara, Italy
- International Agency for Pharma Standard Supplements (IAPPS), Pescara, Italy
| | - Claudia Scipione
- IRVINE3 and Nicolaides Labs, Circulation Sciences and San Valentino, Vascular Screening Project, Pescara, Italy
| | - Valeria Scipione
- IRVINE3 and Nicolaides Labs, Circulation Sciences and San Valentino, Vascular Screening Project, Pescara, Italy
| | - David Cox
- IRVINE3 and Nicolaides Labs, Circulation Sciences and San Valentino, Vascular Screening Project, Pescara, Italy
| | - Umberto Cornelli
- IRVINE3 and Nicolaides Labs, Circulation Sciences and San Valentino, Vascular Screening Project, Pescara, Italy
- International Agency for Pharma Standard Supplements (IAPPS), Pescara, Italy
| | - Roberto Cotellese
- IRVINE3 and Nicolaides Labs, Circulation Sciences and San Valentino, Vascular Screening Project, Pescara, Italy
- International Agency for Pharma Standard Supplements (IAPPS), Pescara, Italy
- Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, Chieti, Italy
| | - Mark Dugall
- IRVINE3 and Nicolaides Labs, Circulation Sciences and San Valentino, Vascular Screening Project, Pescara, Italy
- International Agency for Pharma Standard Supplements (IAPPS), Pescara, Italy
| | - Morio Hosoi
- IRVINE3 and Nicolaides Labs, Circulation Sciences and San Valentino, Vascular Screening Project, Pescara, Italy
- International Agency for Pharma Standard Supplements (IAPPS), Pescara, Italy
| | - Marcello Corsi
- IRVINE3 and Nicolaides Labs, Circulation Sciences and San Valentino, Vascular Screening Project, Pescara, Italy
- International Agency for Pharma Standard Supplements (IAPPS), Pescara, Italy
| | - Beatrice Feragalli
- IRVINE3 and Nicolaides Labs, Circulation Sciences and San Valentino, Vascular Screening Project, Pescara, Italy
- International Agency for Pharma Standard Supplements (IAPPS), Pescara, Italy
- Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, Chieti, Italy
| |
Collapse
|
10
|
Belcaro G, Cesarone MR, Scipione C, Scipione V, Cornelli U, Cotellese R, Dugall M, Hosoi M, Corsi M, Feragalli B, Cox D, Pizzicannella G. Efficacy of the combination Pycnogenol® and Centellicum® on preventing the progression of atherosclerotic plaques: a morphological study. Panminerva Med 2023; 65:283-285. [PMID: 36789998 DOI: 10.23736/s0031-0808.22.04759-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Affiliation(s)
- Gianni Belcaro
- Irvine3 and Nicolaides Labs, Circulation Sciences and San Valentino, Vascular Screening Center (Dpt. Med Or. Biotec, Sciences) Ch-Pe, University, Pescara, Italy -
- Nicolaides' Lab, Spoltore, Pescara, Italy -
| | - Maria R Cesarone
- Irvine3 and Nicolaides Labs, Circulation Sciences and San Valentino, Vascular Screening Center (Dpt. Med Or. Biotec, Sciences) Ch-Pe, University, Pescara, Italy
- Nicolaides' Lab, Spoltore, Pescara, Italy
| | - Claudia Scipione
- Irvine3 and Nicolaides Labs, Circulation Sciences and San Valentino, Vascular Screening Center (Dpt. Med Or. Biotec, Sciences) Ch-Pe, University, Pescara, Italy
- Nicolaides' Lab, Spoltore, Pescara, Italy
| | - Valeria Scipione
- Irvine3 and Nicolaides Labs, Circulation Sciences and San Valentino, Vascular Screening Center (Dpt. Med Or. Biotec, Sciences) Ch-Pe, University, Pescara, Italy
| | - Umberto Cornelli
- Irvine3 and Nicolaides Labs, Circulation Sciences and San Valentino, Vascular Screening Center (Dpt. Med Or. Biotec, Sciences) Ch-Pe, University, Pescara, Italy
| | - Roberto Cotellese
- Irvine3 and Nicolaides Labs, Circulation Sciences and San Valentino, Vascular Screening Center (Dpt. Med Or. Biotec, Sciences) Ch-Pe, University, Pescara, Italy
| | - Mark Dugall
- Irvine3 and Nicolaides Labs, Circulation Sciences and San Valentino, Vascular Screening Center (Dpt. Med Or. Biotec, Sciences) Ch-Pe, University, Pescara, Italy
| | - Morio Hosoi
- Irvine3 and Nicolaides Labs, Circulation Sciences and San Valentino, Vascular Screening Center (Dpt. Med Or. Biotec, Sciences) Ch-Pe, University, Pescara, Italy
| | - Marcello Corsi
- Irvine3 and Nicolaides Labs, Circulation Sciences and San Valentino, Vascular Screening Center (Dpt. Med Or. Biotec, Sciences) Ch-Pe, University, Pescara, Italy
| | - Beatrice Feragalli
- Irvine3 and Nicolaides Labs, Circulation Sciences and San Valentino, Vascular Screening Center (Dpt. Med Or. Biotec, Sciences) Ch-Pe, University, Pescara, Italy
| | - David Cox
- Irvine3 and Nicolaides Labs, Circulation Sciences and San Valentino, Vascular Screening Center (Dpt. Med Or. Biotec, Sciences) Ch-Pe, University, Pescara, Italy
- Nicolaides' Lab, Spoltore, Pescara, Italy
| | - Giuseppe Pizzicannella
- Irvine3 and Nicolaides Labs, Circulation Sciences and San Valentino, Vascular Screening Center (Dpt. Med Or. Biotec, Sciences) Ch-Pe, University, Pescara, Italy
| |
Collapse
|
11
|
Belcaro G, Cox D, Cesarone MR, Scipione C, Scipione V, Dugall M, Hu S, Corsi M, Cornelli U, Feragalli B, Cotellese R, Selvaggi F. Robuvit® reduces fatigue after chemotherapy for colon cancer. A pilot registry study. Minerva Surg 2023:S2724-5691.23.09885-4. [PMID: 36995285 DOI: 10.23736/s2724-5691.23.09885-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/31/2023]
Abstract
BACKGROUND The aim of this pilot registry study was to evaluate the efficacy of Robuvit® (oak wood extract) on residual fatigue due to convalescence in otherwise healthy subjects within one month after surgery and chemotherapy for colon cancer. Robuvit® has been clinically tested in subjects with fatigue (chronic fatigue syndrome), post-traumatic stress disorder, convalescence and burnout. METHODS One group of patients followed the standard management (SM) and was designated as control group while the supplementation group followed the SM and additionally took two Robuvit® capsules daily for six weeks (200 mg/day).The main study endpoints were the Karnofsky performance scale index, handgrip strength in kg, fitness test score on a treadmill, self-assessed work ability, fatigue score, oxidative stress and carcinoembryonic antigen (CEA) plasma levels. In addition, the mood of the patients was assessed using the 'brief mood introspection scale', BMIS. RESULTS Fifty-one subjects with fatigue linked to convalescence within 1 month after chemotherapy for colon cancer completed the study, 29 in the Robuvit® group and 22 as controls. The two management groups were comparable for age and sex distribution. The main investigation parameters were also comparable at inclusion. No side effects or tolerability problems were observed in the six weeks of follow-up. Occasional use of painkillers, antinausea medication or anti-inflammatory agents was accepted. After six weeks, Robuvit® supplementation significantly improved the Karnofsky performance scale index compared to controls. Hand grip strength (dynamometry), treadmill fitness test score and the self-assessed work ability were significantly improved with Robuvit® as well. The fatigue score after six weeks was significantly improved with Robuvit® (P<0.05) in comparison with SM controls. Mood was significantly improved after 6 weeks in the Robuvit® patients compared to the control group. The examined study parameters improved in the patients of the control group as well, during a normal postchemotherapy convalescence, but in a lesser extend when compared to the supplementation group. Oxidative stress was high at inclusion in both groups. The decrease in oxidative stress - as plasma free radicals - was significantly higher with the supplementation (P<0.05). CEA values were within the normal values from inclusion and in the 6 weeks of the registry in all subjects. CONCLUSIONS In conclusion, Robuvit® helps to reduce fatigue after chemotherapy and improves strength, performance, fitness, work ability and mood in these patients, without exposing them to the risk of side effects.
Collapse
Affiliation(s)
- Gianni Belcaro
- Irvine3 Labs, San Valentino Vascular Screening Project, Pescara, Italy -
| | - David Cox
- Irvine3 Labs, San Valentino Vascular Screening Project, Pescara, Italy
| | - Maria R Cesarone
- Irvine3 Labs, San Valentino Vascular Screening Project, Pescara, Italy
| | - Claudia Scipione
- Irvine3 Labs, San Valentino Vascular Screening Project, Pescara, Italy
| | - Valeria Scipione
- Irvine3 Labs, San Valentino Vascular Screening Project, Pescara, Italy
| | - Mark Dugall
- Irvine3 Labs, San Valentino Vascular Screening Project, Pescara, Italy
| | - Shu Hu
- Irvine3 Labs, San Valentino Vascular Screening Project, Pescara, Italy
| | - Marcello Corsi
- Irvine3 Labs, San Valentino Vascular Screening Project, Pescara, Italy
| | - Umberto Cornelli
- Irvine3 Labs, San Valentino Vascular Screening Project, Pescara, Italy
| | | | - Roberto Cotellese
- DSMO-Biotec, University of Chieti-Pescara, Chieti, Italy
- Outpatients Vascular Surgery, School of General Surgery, University of Chieti-Pescara, Chieti, Italy
| | - Federico Selvaggi
- DSMO-Biotec, University of Chieti-Pescara, Chieti, Italy
- Outpatients Vascular Surgery, School of General Surgery, University of Chieti-Pescara, Chieti, Italy
| |
Collapse
|
12
|
Hu S, Belcaro G, Hosoi M, Cesarone MR, Scipione V, Scipione C, Dugall M, Feragalli B, Cotellese R. Prevention of early lymphatic disease in women with Robuvit®: a new supplementary solution? Panminerva Med 2023; 65:91-92. [PMID: 36178110 DOI: 10.23736/s0031-0808.22.04754-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Shuh Hu
- Irvine3 Labs, Department SMOBiotec, G. D'Annunzio University, Chieti-Pescara University, Chieti, Chieti-Pescara, Italy.,IA-PSS: International Agency for Pharma-Standard Supplement, Pescara, Chieti-Pescara, Italy
| | - Gianni Belcaro
- Irvine3 Labs, Department SMOBiotec, G. D'Annunzio University, Chieti-Pescara University, Chieti, Chieti-Pescara, Italy - .,IA-PSS: International Agency for Pharma-Standard Supplement, Pescara, Chieti-Pescara, Italy
| | - Morio Hosoi
- Irvine3 Labs, Department SMOBiotec, G. D'Annunzio University, Chieti-Pescara University, Chieti, Chieti-Pescara, Italy.,IA-PSS: International Agency for Pharma-Standard Supplement, Pescara, Chieti-Pescara, Italy
| | - Maria R Cesarone
- Irvine3 Labs, Department SMOBiotec, G. D'Annunzio University, Chieti-Pescara University, Chieti, Chieti-Pescara, Italy.,IA-PSS: International Agency for Pharma-Standard Supplement, Pescara, Chieti-Pescara, Italy
| | - Valeria Scipione
- Irvine3 Labs, Department SMOBiotec, G. D'Annunzio University, Chieti-Pescara University, Chieti, Chieti-Pescara, Italy.,IA-PSS: International Agency for Pharma-Standard Supplement, Pescara, Chieti-Pescara, Italy
| | - Claudia Scipione
- Irvine3 Labs, Department SMOBiotec, G. D'Annunzio University, Chieti-Pescara University, Chieti, Chieti-Pescara, Italy.,IA-PSS: International Agency for Pharma-Standard Supplement, Pescara, Chieti-Pescara, Italy
| | - Mark Dugall
- Irvine3 Labs, Department SMOBiotec, G. D'Annunzio University, Chieti-Pescara University, Chieti, Chieti-Pescara, Italy.,IA-PSS: International Agency for Pharma-Standard Supplement, Pescara, Chieti-Pescara, Italy
| | - Beatrice Feragalli
- Irvine3 Labs, Department SMOBiotec, G. D'Annunzio University, Chieti-Pescara University, Chieti, Chieti-Pescara, Italy.,IA-PSS: International Agency for Pharma-Standard Supplement, Pescara, Chieti-Pescara, Italy
| | - Roberto Cotellese
- Irvine3 Labs, Department SMOBiotec, G. D'Annunzio University, Chieti-Pescara University, Chieti, Chieti-Pescara, Italy.,IA-PSS: International Agency for Pharma-Standard Supplement, Pescara, Chieti-Pescara, Italy
| |
Collapse
|
13
|
Belcaro G, Cornelli U, Hosoi M, Cox D, Dugall M, Cesarone MR, Ledda A, Scipione V, Scipione C, Feragalli B, Cotellese R. Intestinal fat absorption shifting: polyglucosamine biopolymer controls lipids and weight and reduces the progression of subclinical atherosclerosis. Minerva Gastroenterol (Torino) 2023; 69:114-122. [PMID: 36856275 DOI: 10.23736/s2724-5985.22.03280-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/02/2023]
Abstract
BACKGROUND Intestinal fat absorption shifting (IFAS) can be obtained in hyperlipidemic subjects with polyglucosamine biopolymer (BP) able to segregate most metabolic fats in the gut, making them unavailable for intestinal interaction (shift). The aim of this study was to evaluate the effects of a SM (standard management) for hyperlipidemia in asymptomatic subjects for primary cardiovascular prevention focusing on arterial wall morphology (IMT thickness) in comparison to SM associated to the administration of the BP. METHODS Two groups of comparable subjects (SM and SM+oral BP, 3 g/day) were considered; subjects were managed - in a supplement, pilot registry - for a year. Weight, fat mass, lipid profile, oxidative stress, IMT (carotids), the presence of granulations at the internal arterial layers and "near wall low density 'bubbles' were observed and compared at 1 year of management. A non-parallel, comparable group of subjects (102) using a statin for the same conditions was used as a reference population. RESULTS Two hundred eighty-four subjects completed one year (140 in the SM group and 144 in the SM+BP group). Compliance was optimal with (96.3% of the table correctly used) with no side effects. BMI, fat mass and oxidative stress decreased more in the SM+BP group (P<0.05). Cholesterol and triglycerides levels were significantly improved with BP (P<0.05). IMT measurements were significantly decreased (P<0.05) in the SM+BP group (as for the intimal granulation/bubbles) with minimal variations in the comparative SM group. In the statin group, the lipid profile was modified (P<0.05) but not the IMT and the rate of drop outs was higher (15.7%); these patients stopped the management; in 23% of these subjects muscular pain not seen with BP, was observed. CONCLUSIONS These results indicate positive effects of IFAS due to BP on IMT and arterial wall morphology and weight after 12 months. Fat shifting at intestinal level and the reduction of oxidative stress limit lipid oxidation/deposition into the arterial wall.
Collapse
Affiliation(s)
- Gianni Belcaro
- Irvine3 Institute and International Agency for Pharma-Standard Supplements, Pescara, Chieti-Pescara, Italy -
| | | | - Morio Hosoi
- Irvine3 Institute and International Agency for Pharma-Standard Supplements, Pescara, Chieti-Pescara, Italy
| | - David Cox
- Irvine3 Institute and International Agency for Pharma-Standard Supplements, Pescara, Chieti-Pescara, Italy
| | - Mark Dugall
- Irvine3 Institute and International Agency for Pharma-Standard Supplements, Pescara, Chieti-Pescara, Italy
| | - Maria R Cesarone
- Irvine3 Institute and International Agency for Pharma-Standard Supplements, Pescara, Chieti-Pescara, Italy
| | - Andrea Ledda
- Irvine3 Institute and International Agency for Pharma-Standard Supplements, Pescara, Chieti-Pescara, Italy
| | - Valeria Scipione
- Irvine3 Institute and International Agency for Pharma-Standard Supplements, Pescara, Chieti-Pescara, Italy
| | - Claudia Scipione
- Irvine3 Institute and International Agency for Pharma-Standard Supplements, Pescara, Chieti-Pescara, Italy
| | - Beatrice Feragalli
- SMOBiotec Department, D'Annunzio University, Chieti, Chieti-Pescara, Italy
| | - Roberto Cotellese
- SMOBiotec Department, D'Annunzio University, Chieti, Chieti-Pescara, Italy
| |
Collapse
|
14
|
Cesarone MR, Belcaro G, Cornelli U, Hosoi M, Scipione V, Scipione C, Dugall M, Feragalli B, Pellegrini L, Cotellese R, Bottari A, Ledda A. Effects of Pycnogenol® in women with postmenopausal symptoms: a 90-day comparative study. Panminerva Med 2023:S0031-0808.22.04792-9. [PMID: 36800800 DOI: 10.23736/s0031-0808.22.04792-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Affiliation(s)
- Maria R Cesarone
- Irvine3 Institute, San Valentino, Pescara, Italy.,IAPSS: International Agency for Pharma-Standard Supplements, Pescara, Italy
| | - Gianni Belcaro
- Irvine3 Institute, San Valentino, Pescara, Italy - .,IAPSS: International Agency for Pharma-Standard Supplements, Pescara, Italy
| | | | - Morio Hosoi
- Irvine3 Institute, San Valentino, Pescara, Italy.,IAPSS: International Agency for Pharma-Standard Supplements, Pescara, Italy
| | - Valeria Scipione
- Irvine3 Institute, San Valentino, Pescara, Italy.,IAPSS: International Agency for Pharma-Standard Supplements, Pescara, Italy
| | - Claudia Scipione
- Irvine3 Institute, San Valentino, Pescara, Italy.,IAPSS: International Agency for Pharma-Standard Supplements, Pescara, Italy
| | - Mark Dugall
- Irvine3 Institute, San Valentino, Pescara, Italy.,IAPSS: International Agency for Pharma-Standard Supplements, Pescara, Italy
| | | | - Luciano Pellegrini
- Irvine3 Institute, San Valentino, Pescara, Italy.,IAPSS: International Agency for Pharma-Standard Supplements, Pescara, Italy
| | | | - Angelica Bottari
- Irvine3 Institute, San Valentino, Pescara, Italy.,IAPSS: International Agency for Pharma-Standard Supplements, Pescara, Italy
| | - Andrea Ledda
- Irvine3 Institute, San Valentino, Pescara, Italy.,IAPSS: International Agency for Pharma-Standard Supplements, Pescara, Italy
| |
Collapse
|
15
|
Cesarone MR, Belcaro G, Cornelli U, Feragalli B, Scipione C, Scipione V, Dugall M, Hosoi M, Cotellese R, Corsi M. Chronic venous insufficiency and microangiopathy: supplementation with Pycnogenol® reduces the progression of venous disease in women. Panminerva Med 2022; 64:564-566. [PMID: 36533666 DOI: 10.23736/s0031-0808.22.04771-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Affiliation(s)
- Maria R Cesarone
- Irvine3 and Nicolaides Labs Circulation Sciences & San Valentino, Vascular Screening Center, Pescara, Italy
| | - Gianni Belcaro
- Irvine3 and Nicolaides Labs Circulation Sciences & San Valentino, Vascular Screening Center, Pescara, Italy -
| | - Umberto Cornelli
- Irvine3 and Nicolaides Labs Circulation Sciences & San Valentino, Vascular Screening Center, Pescara, Italy
| | - Beatrice Feragalli
- Department of Medical, Oral and Biotechnological Sciences, G. d'Annunzio University, Chieti, Italy
| | - Claudia Scipione
- Irvine3 and Nicolaides Labs Circulation Sciences & San Valentino, Vascular Screening Center, Pescara, Italy
| | - Valeria Scipione
- Irvine3 and Nicolaides Labs Circulation Sciences & San Valentino, Vascular Screening Center, Pescara, Italy
| | - Mark Dugall
- Irvine3 and Nicolaides Labs Circulation Sciences & San Valentino, Vascular Screening Center, Pescara, Italy
| | - Morio Hosoi
- Irvine3 and Nicolaides Labs Circulation Sciences & San Valentino, Vascular Screening Center, Pescara, Italy
| | - Roberto Cotellese
- Department of Medical, Oral and Biotechnological Sciences, G. d'Annunzio University, Chieti, Italy
| | - Marcello Corsi
- Irvine3 and Nicolaides Labs Circulation Sciences & San Valentino, Vascular Screening Center, Pescara, Italy
| |
Collapse
|
16
|
Belcaro G, Cesarone MR, Cornelli U, Dugall M. A standard model for venous thrombosis. A quantum view. Minerva Med 2022; 113:875-876. [PMID: 36475535 DOI: 10.23736/s0026-4806.22.08050-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Gianni Belcaro
- The IRVINE3 Institute, Oolex Center, Quantum Labs, Chieti, Italy -
| | - Maria R Cesarone
- The IRVINE3 Institute, Oolex Center, Quantum Labs, Chieti, Italy
| | - Umberto Cornelli
- The IRVINE3 Institute, Oolex Center, Quantum Labs, Chieti, Italy
| | - Mark Dugall
- The IRVINE3 Institute, Oolex Center, Quantum Labs, Chieti, Italy
| |
Collapse
|
17
|
Belcaro G, Cornelli U, Hosoi M, Cesarone MR, Scipione V, Scipione C, Dugall M, Feragalli B, Pellegrini L, Cotellese R. Intestinal fat absorption shifting (IFAS) with a chitosan biopolymer slows down the progression of subclinical atherosclerosis. A pilot study. Minerva Gastroenterol (Torino) 2022; 68:223-230. [PMID: 35179340 DOI: 10.23736/s2724-5985.22.03141-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Intestinal fat absorption shifting (IFAS) can be achieved with a chitosan biopolymer (BP) able to retain most fats in the gut so that they are available to the intestinal microbiota (shift). The aim of this study was to evaluate the effects of the standard management (SM) of asymptomatic cardiovascular disease prevention on intima-media thickness (IMT) in comparison with SM combined with BP. METHODS Two groups (SM and SM+3 g BP/day) were compared. They consisted of 86 and 81 subjects respectively treated for 6 months. Anthropometric variables, vital signs, fat mass, lipid profile, oxidative stress, carotid IMT, granulations at the IM layer and near-wall low density bubbles were measured. RESULTS Seventy-eight cases in the SM group and 81 in the SM+BP group completed the management period. Compliance was optimal (>97%) with no side effects. The anthropometric variables, vital signs, fat mass and oxidative stress were significantly lower only in the SM+BP group (P<0.05). Cholesterol and triglyceride levels improved with BP use (P<0.05). The changes in IMT were reduced significantly (P<0.05) in the SM+BP group only. The same was true for intimal granulation/bubbles. CONCLUSIONS The preliminary results suggest that the IFAS caused by BP has a positive effect on IMT and arterial wall structure (thickness and low-density bubbles) even during a short period of management. The intestinal fat shifting and reduction in oxidative stress seem to limit lipid oxidation and deposition on the arterial wall.
Collapse
Affiliation(s)
- Gianni Belcaro
- Irvine 3 Institute, San Valentino, Pescara, Italy - .,International Agency for Pharma-Standard Supplements - IAPSS, Pescara, Italy -
| | | | - Morio Hosoi
- Irvine 3 Institute, San Valentino, Pescara, Italy.,International Agency for Pharma-Standard Supplements - IAPSS, Pescara, Italy
| | - Maria R Cesarone
- Irvine 3 Institute, San Valentino, Pescara, Italy.,International Agency for Pharma-Standard Supplements - IAPSS, Pescara, Italy
| | - Valeria Scipione
- Irvine 3 Institute, San Valentino, Pescara, Italy.,International Agency for Pharma-Standard Supplements - IAPSS, Pescara, Italy
| | - Claudia Scipione
- Irvine 3 Institute, San Valentino, Pescara, Italy.,International Agency for Pharma-Standard Supplements - IAPSS, Pescara, Italy
| | - Mark Dugall
- Irvine 3 Institute, San Valentino, Pescara, Italy.,International Agency for Pharma-Standard Supplements - IAPSS, Pescara, Italy
| | | | - Luciano Pellegrini
- Irvine 3 Institute, San Valentino, Pescara, Italy.,International Agency for Pharma-Standard Supplements - IAPSS, Pescara, Italy
| | | |
Collapse
|
18
|
Cox D, Belcaro G, Cesarone MR, Cotellese R, Dugall M, Feragalli B, Hosoi M, Corsi M, Luzzi R. Primary benign back pain: supplementation with Pycnogenol®. Panminerva Med 2021; 63:472-477. [PMID: 34915691 DOI: 10.23736/s0031-0808.20.03961-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Back pain (BP) is one of the most common problems seen by general practitioners. The aim of this pilot registry study was to evaluate the effects of Pycnogenol® (French Maritime Pine Bark extract) on pain, mobility and muscle spasm in patients with recurring episodes of back pain without any other clinical condition. METHODS The registry follow-up lasted 3 weeks. Subjects used either SM (standard management), including mild exercise and 3 days of resting or immobilization - or SM+Pycnogenol® 200 mg/day (4 cps/day). RESULTS Eighty-two subjects were included in the study, 23 took Pycnogenol® and 59 were in the SM group. No safety problems or tolerability problems were observed with Pycnogenol® or with the SM. The two groups, SM and SM+Pycnogenol®, were comparable at inclusion. A prevalent localization to the lower part of the back/spine was observed in all patients of both groups. The improvement in Karnofsky performance status Scale - expressing the global physical capacity of the individuals - during the 3 weeks of follow-up was significantly higher and faster in the Pycnogenol® group (P<0.05) compared to SM. Patients were able to restart physical training in 3 weeks with Pycnogenol® (in comparison with 4.5 weeks with SM only). The decrease in back pain score (VASL score) was faster and more pronounced with Pycnogenol® (P<0.05) compared to SM. Oxidative stress was significantly reduced in subjects using Pycnogenol® (P<0.05) while it remained elevated in the control group. The use of the rescue medication doses (ibuprofen) was significantly higher in the SM only (P<0.05) in comparison with SM+Pycnogenol®. CONCLUSIONS Pycnogenol® appears to be an effective and safe supplementary management in healthy subjects with idiopathic BP. Mobility, pain, general physical capacity and oxidative stress improved in only a week with further improvements up to 4 weeks in most patients; results appear to be better and faster with Pycnogenol® supplementation than with SM alone.
Collapse
Affiliation(s)
- David Cox
- IRVINE3 Vascular/Circulation Labs, Pescara, Italy
| | - Gianni Belcaro
- IRVINE3 Vascular/Circulation Labs, Pescara, Italy - .,Radiology, Department of Medical, Oral and Biotechnological Sciences, D'Annunzio University, Pescara, Italy.,IAAPS, International Agency for Pharma Standard Supplements, Pescara, Italy
| | - Maria R Cesarone
- IRVINE3 Vascular/Circulation Labs, Pescara, Italy.,Radiology, Department of Medical, Oral and Biotechnological Sciences, D'Annunzio University, Pescara, Italy.,IAAPS, International Agency for Pharma Standard Supplements, Pescara, Italy
| | | | - Mark Dugall
- IRVINE3 Vascular/Circulation Labs, Pescara, Italy.,Radiology, Department of Medical, Oral and Biotechnological Sciences, D'Annunzio University, Pescara, Italy.,IAAPS, International Agency for Pharma Standard Supplements, Pescara, Italy
| | - Beatrice Feragalli
- Radiology, Department of Medical, Oral and Biotechnological Sciences, D'Annunzio University, Pescara, Italy
| | - Morio Hosoi
- IRVINE3 Vascular/Circulation Labs, Pescara, Italy
| | | | | |
Collapse
|
19
|
Cotellese R, Hu S, Cesarone MR, Belcaro G, Dugall M, Feragalli B, Hosoi M, Ippolito E, Corsi M, Luzzi R. Pycnogenol® supplementation prevents inflammation and symptoms in recurrent, non-severe urinary infections. Panminerva Med 2021; 63:343-348. [PMID: 34738775 DOI: 10.23736/s0031-0808.20.03853-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND The aim of this pilot, registry study was to evaluate the prophylactic effects of oral supplementation with Pycnogenol® (150 mg/day) in subjects with previous history of recurrent (urinary tract infections (UTI) in a 2-month open follow-up. METHODS subjects with recurrent-UTIs, defined by: 1) at least three symptomatic UTIs over the past year; 2) two episodes of UTI's in the past six months; 3) symptoms of UTIs with urinalysis without bacterial presence, were included in the study. Pycnogenol® was supplemented at the dose of 150 mg/day for 2 months. RESULTS The two groups of subjects (supplement and controls, each including 25 subjects) were demographically and clinically comparable at baseline. No side effects or tolerability problems were observed. The registry evaluated the number of recurrent UTIs in two months; there was a limited decrease in the rate of recurrent UTIs, in comparison with the period before inclusion of 9.93% in the standard management group in comparison with a more important decrease in the Pycnogenol® group (-50.1%; P<0.05). The number of episodes decreased from 3.22±0.4 to 2.9±0.3 in the control group in 2 months versus a decrease from 3.1±0.5 to 1.6±0.6 in the Pycnogenol® group. The number of infection-free subjects at the end of the two-month registry study was significantly higher with the supplement (P<0.05) than in controls. Oxidative stress measured as plasma free radicals at inclusion was 388±22 Carr units in the control group and resulted unchanged (not significant) at the end of the study (379±21 Carr units). In the supplement group, there was a significant decrease in oxidative stress from 389±24 to 227±14 Carr units at the end of the study (P<0.05). CONCLUSIONS This pilot registry indicates that prophylaxis with Pycnogenol® decreases the occurrence of UTIs both in men and women without side effects and with a good tolerability. The effects of Pycnogenol® in these patients - including the control of oxidative stress - may be very important, particularly when a predominantly inflammatory component (UTI without infection or with a minimal bacterial component due to bacterial fragments) is present and maintains the inflammatory process.
Collapse
Affiliation(s)
- Roberto Cotellese
- IRVINE3 Vascular/Circulation Labs, Chieti-Pescara University, Pescara, Italy.,International Agency for Pharma Standard Supplements (IAAPS), Pescara, Italy
| | - Shu Hu
- IRVINE3 Vascular/Circulation Labs, Chieti-Pescara University, Pescara, Italy.,International Agency for Pharma Standard Supplements (IAAPS), Pescara, Italy
| | - Maria R Cesarone
- IRVINE3 Vascular/Circulation Labs, Chieti-Pescara University, Pescara, Italy.,International Agency for Pharma Standard Supplements (IAAPS), Pescara, Italy
| | - Gianni Belcaro
- IRVINE3 Vascular/Circulation Labs, Chieti-Pescara University, Pescara, Italy - .,International Agency for Pharma Standard Supplements (IAAPS), Pescara, Italy
| | - Mark Dugall
- IRVINE3 Vascular/Circulation Labs, Chieti-Pescara University, Pescara, Italy.,International Agency for Pharma Standard Supplements (IAAPS), Pescara, Italy
| | - Beatrice Feragalli
- IRVINE3 Vascular/Circulation Labs, Chieti-Pescara University, Pescara, Italy.,International Agency for Pharma Standard Supplements (IAAPS), Pescara, Italy
| | - Morio Hosoi
- IRVINE3 Vascular/Circulation Labs, Chieti-Pescara University, Pescara, Italy.,International Agency for Pharma Standard Supplements (IAAPS), Pescara, Italy
| | - Edmondo Ippolito
- IRVINE3 Vascular/Circulation Labs, Chieti-Pescara University, Pescara, Italy.,International Agency for Pharma Standard Supplements (IAAPS), Pescara, Italy
| | - Marcello Corsi
- IRVINE3 Vascular/Circulation Labs, Chieti-Pescara University, Pescara, Italy.,International Agency for Pharma Standard Supplements (IAAPS), Pescara, Italy
| | - Roberta Luzzi
- IRVINE3 Vascular/Circulation Labs, Chieti-Pescara University, Pescara, Italy.,International Agency for Pharma Standard Supplements (IAAPS), Pescara, Italy
| |
Collapse
|
20
|
Cotellese R, Ledda A, Belcaro G, Cesarone MR, Scipione C, Scipione V, Dugall M, Feragalli B, Riva A, Allegrini P, Petrangolini G, Togni S. Anthocran® Phytosome®: Prevention of Recurring Urinary Infections and Symptoms after Catheterization. J Diet Suppl 2021; 20:55-67. [PMID: 34632933 DOI: 10.1080/19390211.2021.1972074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
In this preliminary pilot registry study, we investigated the effects of the oral supplementation of a standardized cranberry extract (Anthocran® Phytosome®, Indena) delivered by a lecithin-based system, for the prophylactic management of recurrent-urinary tract infections (R-UTIs). We included 64 otherwise healthy subjects who underwent a surgical procedure and required post-surgical urinary catheterization for high-risk UTIs or a previous history of R-UTIs. Patients were given supplementation with the standardized cranberry extract at the dose of either 120 mg/day (n = 12) or 240 mg/day (n = 12) or assigned to a control group consisting of standard management (SM; n = 18) or nitrofurantoin administration (n = 22) for 4 weeks. After 4 weeks, patients receiving the standardized cranberry supplementation reported to have a more effective reduction in UTI symptoms, as assessed on the visual analogue scale, compared with patients in the SM or nitrofurantoin groups. The occurrence of hematuria and urine bacterial contamination were decreased among patients treated with the supplement compared with controls (p < 0.05). The cranberry extract was also superior to the control management in terms of recurrence of signs/symptoms, with none of the patients in this group suffering from a R-UTI in the 3 months following the study end (p < 0.05). The supplementation showed an optimal safety profile, with no significant adverse events and no drop-outs in the supplement group. This registry shows that this cranberry extract is effective as a supplementary, preventive management in preventing post-operative, post-catheter UTIs; the product has a good tolerability profile.
Collapse
Affiliation(s)
| | - Andrea Ledda
- Irvine3 Labs and San Valentino Vascular Screening Project DScMedBiotec, Chieti-Pescara University, Chieti, Italy
| | - Gianni Belcaro
- Irvine3 Labs and San Valentino Vascular Screening Project DScMedBiotec, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPSS), Pescara, Italy
| | - Maria R Cesarone
- Irvine3 Labs and San Valentino Vascular Screening Project DScMedBiotec, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPSS), Pescara, Italy
| | - Claudia Scipione
- Irvine3 Labs and San Valentino Vascular Screening Project DScMedBiotec, Chieti-Pescara University, Chieti, Italy
| | - Valeria Scipione
- Irvine3 Labs and San Valentino Vascular Screening Project DScMedBiotec, Chieti-Pescara University, Chieti, Italy
| | - Mark Dugall
- Irvine3 Labs and San Valentino Vascular Screening Project DScMedBiotec, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPSS), Pescara, Italy
| | | | | | | | | | | |
Collapse
|
21
|
Belcaro G, Cesarone MR, Saggino A, Dugall M, Hu S, Scipione C, Scipione V, Cornelli U, Hosoi M, Cotellese R, Cox D, Corsi M, Feragalli B. Prevention of work-related stress, fatigue, loss of cognitive function, attention and recovery of stamina with Robuvit® in professionals with increased oxidative stress. Minerva Med 2021; 113:518-525. [PMID: 34542952 DOI: 10.23736/s0026-4806.21.07776-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
AIM The aim of this open, pilot supplement registry study was to evaluate the protective, preventive effects of Robuvit® on professional-related fatigue symptoms and on aspects of cognitive functions, professional attitudes and decision-making in healthy nurses under professional stress and with increased oxidative stress. RESULTS In total, 40 subjects, aged 30 - 37, completed the 4-week registry study. A control group of 20 subjects used only the standard management (SM) and one group of 20 subjects took 300 mg Robuvit®. Safety and tolerability of Robuvit® were optimal. The two registry groups were comparable at inclusion. The overall scores of the real daily life & tasks questionnaire after 4 weeks were significantly higher in the Robuvit® group (p<0.05) as compared to controls. It increased from 4.3±0.4 at baseline to 6.78±0.8 after 4 weeks of Robuvit® intake and from 4.2±0.5 to 5.12±1.0 in the control group. The supplementation significantly improved the objective perception of fatigue in comparison with controls (p<0.05). A practical professional score evaluation provided an indication of professional attitude and stamina, in difficult, stressful working conditions under continuous pressure. The results showed that after 4-week supplementation all assessed parameters improved significantly and the difference with controls was statistically significant (p<0.05). Furthermore,oxidative stress as plasma free radicals decreased significant in the Robuvit® group (p<0.05) but not in the control group. CONCLUSIONS Robuvit® supplementation appears to improve most symptoms related to work-induced fatigue, stress and cognitive function and supports stamina. Further evaluations need to be planned according to the concept of this pilot registry in a field that requires more attention.
Collapse
Affiliation(s)
- Gianni Belcaro
- Irvine3 Labs Institute and OOLEX Research center, Pescara, Italy -
| | - Maria R Cesarone
- Irvine3 Labs Institute and OOLEX Research center, Pescara, Italy
| | - Aristide Saggino
- Psychology Faculty, D'Annunzio University, Ch - Pe University, Pescara, Italy
| | - Mark Dugall
- Irvine3 Labs Institute and OOLEX Research center, Pescara, Italy
| | - Shu Hu
- Irvine3 Labs Institute and OOLEX Research center, Pescara, Italy
| | - Claudia Scipione
- Irvine3 Labs Institute and OOLEX Research center, Pescara, Italy
| | - Valeria Scipione
- Irvine3 Labs Institute and OOLEX Research center, Pescara, Italy
| | - Umberto Cornelli
- Irvine3 Labs Institute and OOLEX Research center, Pescara, Italy
| | - Morio Hosoi
- Irvine3 Labs Institute and OOLEX Research center, Pescara, Italy
| | - Roberto Cotellese
- RADIOLOGY INSTITUTE Dpt. Sc Med or Biotec, Ch-Pe University, Pescara, Italy
| | - David Cox
- Irvine3 Labs Institute and OOLEX Research center, Pescara, Italy
| | - Marcello Corsi
- Irvine3 Labs Institute and OOLEX Research center, Pescara, Italy
| | - Beatrice Feragalli
- RADIOLOGY INSTITUTE Dpt. Sc Med or Biotec, Ch-Pe University, Pescara, Italy
| |
Collapse
|
22
|
Cesarone MR, Hu S, Belcaro G, Cornelli U, Feragalli B, Corsi M, Bombardelli E, Cotellese R, Hosoi M, Rosenkvist L. Pycnogenol®-Centellicum® supplementation improves lung fibrosis and Post-Covid-19 lung healing. Minerva Med 2021; 113:135-140. [PMID: 34180638 DOI: 10.23736/s0026-4806.20.07225-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
AIM The aim of this study was the evaluation of the combination of Pycnogenol® (150 mg/day) and Centella asiatica (Centellicum® 3 x 225 mg/day) (PY-CE) for 8 months in subjects with sequelae of idiopathic interstitial pneumonia (IIP). Recently, post-COVID-19 lung disease is emerging with large numbers of patients left with chronic lung conditions. Considering the antifibrotic activity of the combination PY-CE, we also tested this supplementary management in post-COVID-19 lung patients. RESULTS 19 subjects with idiopathic interstitial pneumonia (IIP) were included in the study. High Resolution CT scans at inclusion confirmed the presence of lung fibrosis: 10 patients were treated with the Pycnogenol® Centellicum® combination and 9 subjects with standard management (SM) served as controls. Oxidative stress that was very high in all subjects at inclusion, decreased significantly in the supplement group (p<0.05). The Karnofsky performance scale index significantly improved in the supplement group in comparison with controls (p<0.05). The symptoms (fatigue, muscular pain, dyspnea) were significantly lower after 8 months in supplemented patients (p<0.05) as compared with controls. At the end of the study, the small cystic lesions (honeycombing) and traction bronchiectasis were stable or in partial regression in 4 subjects in the supplemented group (vs none in the control group) with a significant improvement in tissue edema in the supplemented subjects. On ultrasound lung scans the white (more echogenic) fibrotic component at inclusion was 18.5±2.2% in the images in controls vs 19.4±2.7% in the supplement group. At the end of the study, there was no improvement in controls (18.9±2.5%) vs a significant improvement in supplemented subjects (16.2±2.1%; p<0.05). In addition, 18 subjects with post-COVID-19 lung disease were included in the study; 10 patients were treated with the Pycnogenol® Centellicum® combination and evaluated after 4 weeks; 8 patients served as controls. Preliminary results show that symptoms associated with post-COVID-19 lung disease after 4 weeks were significantly improved with the supplement combination (p<0.05). Oxidative stress and the Karnofsky performance scale index scale were significantly improved in the supplements group as compared with controls (p<0.05). CONCLUSIONS According to these observations, Pycnogenol® controls and decreases edema in several conditions and Centellicum® - modulating the apposition of collagen - modulates the development of irregular cicatrization, keloidal scarring and fibrosis. More time is needed to evaluate this effect in a larger number of post-COVID-19 patients with lung disease. This disease has affected millions of subjects worldwide, leaving severe consequences. Pycnogenol® and Centellicum® may improve the residual clinical picture in post-COVID-19 lung disease (PCL) patients and may reduce the number of subjects evolving into lung fibrosis. The evolution from edema to fibrosis seems to be slower or attenuated with this supplement combination both in Idiopathic pulmonary fibrosis (IPF) and in PCL patients.
Collapse
Affiliation(s)
- Maria R Cesarone
- Irvine3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
| | - Shu Hu
- Irvine3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
| | - Gianni Belcaro
- Irvine3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy -
| | - Umberto Cornelli
- Irvine3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
| | - Beatrice Feragalli
- Irvine3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
| | - Marcello Corsi
- Irvine3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
| | - Ezio Bombardelli
- Irvine3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
| | - Roberto Cotellese
- Irvine3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
| | - Morio Hosoi
- Irvine3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
| | - Lars Rosenkvist
- Department of Head and Neck Surgery, Sonderborg Hospital, University of South Denmark, Sonderborg, Denmark
| |
Collapse
|
23
|
Hu S, Belcaro G, Hosoi M, Cesarone MR, Scipione V, Scipione C, Dugall M, Feragalli B, Cotellese R, Maione C. Prevention of diffuse, minimal lymphatic "retention" with Robuvit®: a concept, supplement registry study. Minerva Cardioangiol 2021; 68:197-202. [PMID: 32586070 DOI: 10.23736/s0026-4725.19.05026-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND The aim of this study was to evaluate the effects of the standardized supplement Robuvit® (oak wood extract) in defined diffuse, minimal lymphatic "retention" (DMLR). METHODS Robuvit® has already been investigated in both primary and secondary (post-surgical, post chemo-radiotherapy) lymphatic insufficiency. This registry included subjects with diffuse, minimal lymphatic "retention" (DMLR). The registry management groups included women with mild-moderate limb swelling using standard management (SM) as controls. A second, comparable group used prevention with Robuvit® at the dosage of 3 cp/day (300 mg/day) for 4 weeks. RESULTS No tolerability problems or side effects were observed with the preventive supplementation. The management groups (34 women in total), including 18 women in Robuvit® and 16 in SM were comparable in age and baseline evaluations. After 4 weeks, in the Robuvit® group, edema scale values derived from ultrasound observations decreased significantly (P<0.05) at all measurement's sites, from the proximal (inguinal) level to the more distal (ankle-foot) level. No significant changes in edema were observed in control subjects. Generally, in areas with higher level of edema (distal areas at the foot and ankle), the edema decrease was larger than in more proximal, ultrasound measurement sites. CONCLUSIONS Preventive Robuvit® supplementation appears to be safe and effective in controlling DMLR in subjects without significant or apparent clinical conditions. This preventive, concept study should be extended to a larger population for more meaningful observations.
Collapse
Affiliation(s)
- Shuh Hu
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
| | - Gianni Belcaro
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy -
| | - Morio Hosoi
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
| | - Maria R Cesarone
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
| | - Valeria Scipione
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
| | - Claudia Scipione
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
| | - Mark Dugall
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
| | - Beatrice Feragalli
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
| | - Roberto Cotellese
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
| | - Claudia Maione
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
| |
Collapse
|
24
|
Hu S, Belcaro G, Cesarone MR, Feragalli B, Cotellese R, Dugall M, Scipione C, Scipione V, Maione C, Maramaldi G, Togni S, Riva A. A sport cream (Harpago-Boswellia-ginger-escin) for localized neck/shoulder pain. Minerva Med 2021; 112:255-260. [PMID: 32880419 DOI: 10.23736/s0026-4806.20.06819-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Neck/shoulder, sudden pain, or muscular pain (not associated to structural or bone/joints components), due to fascial or muscular strain is common in active subjects, in non-professional athletes and sports performers. The aim of this supplement registry was the evaluation of a cream based on natural, active ingredients for topical application in supporting the improvement of pain and improving head/neck mobility, possibly minimizing the use of systemic drugs. METHODS The cream includes standardized active ingredients of natural origin as an extract of Harpagophytum procumbes, an extract from Boswellia serrata, a CO2 extract of ginger and escin. Subjects were divided into three groups, all using the standard management (SM) in combination with the Sport Cream or in addition to Flector (diclofenac) patch. RESULTS The groups were comparable and homogeneous at the baseline. No side effects or skin tolerability issues were observed with the Sport Cream nor with the SM or diclofenac patches. Subjects receiving sport cream + SM reported a significant improvement in pain, stiffness, altered mobility and altered working capacity, with a reduced need for rescue medication (diclofenac) compared to subjects in the other two groups. CONCLUSIONS Finally, subjects receiving sport cream + SM reported a more remarkable decrease in skin temperature in the affected area associated to an improvement in clinical symptoms.
Collapse
Affiliation(s)
- Shu Hu
- Irvine3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
- Indena, Milan, Italy
| | - Gianni Belcaro
- Irvine3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy -
- Indena, Milan, Italy
| | - Maria R Cesarone
- Irvine3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
- Indena, Milan, Italy
| | - Beatrice Feragalli
- Irvine3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
- Indena, Milan, Italy
| | - Roberto Cotellese
- Irvine3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
- Indena, Milan, Italy
| | - Mark Dugall
- Irvine3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
- Indena, Milan, Italy
| | - Claudia Scipione
- Irvine3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
- Indena, Milan, Italy
| | - Valeria Scipione
- Irvine3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
- Indena, Milan, Italy
| | - Claudia Maione
- Irvine3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
- Indena, Milan, Italy
| | - Giada Maramaldi
- Irvine3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
- Indena, Milan, Italy
| | - Stefano Togni
- Irvine3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
- Indena, Milan, Italy
| | - Antonella Riva
- Irvine3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
- Indena, Milan, Italy
| |
Collapse
|
25
|
Belcaro G, Corsi M, Agus GB, Cesarone MR, Cornelli U, Cotellese R, Feragalli B, Hu S. Thrombo-prophylaxis prevents thrombotic events in home-managed COVID patients. A registry study. Minerva Med 2021; 111:366-368. [PMID: 33032396 DOI: 10.23736/s0026-4806.20.06688-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Gianni Belcaro
- Oolex Center for COVID, IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy - .,Department of Medical and Oral Sciences and Biotechnologies, Chieti-Pescara University, Pescara, Italy -
| | - Marcello Corsi
- Oolex Center for COVID, IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,Department of Medical and Oral Sciences and Biotechnologies, Chieti-Pescara University, Pescara, Italy
| | | | - Maria R Cesarone
- Oolex Center for COVID, IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,Department of Medical and Oral Sciences and Biotechnologies, Chieti-Pescara University, Pescara, Italy
| | - Umberto Cornelli
- Oolex Center for COVID, IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,Department of Medical and Oral Sciences and Biotechnologies, Chieti-Pescara University, Pescara, Italy
| | - Roberto Cotellese
- Oolex Center for COVID, IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,Department of Medical and Oral Sciences and Biotechnologies, Chieti-Pescara University, Pescara, Italy
| | - Beatrice Feragalli
- Oolex Center for COVID, IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,Department of Medical and Oral Sciences and Biotechnologies, Chieti-Pescara University, Pescara, Italy
| | - Shu Hu
- Oolex Center for COVID, IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,Department of Medical and Oral Sciences and Biotechnologies, Chieti-Pescara University, Pescara, Italy
| |
Collapse
|
26
|
Belcaro G, Hu S, Cesarone MR, Dugall M, Scipione C, Scipione V, Hosoi M, Ledda A, Cornelli U, Feragalli B, Cotellese R. Idiopathic myalgic pain (fibromyalgia): supportive management and prevention with Pycnogenol®. Panminerva Med 2021; 63:46-50. [PMID: 33541059 DOI: 10.23736/s0031-0808.20.03955-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND The aim of this registry study was the prospective evaluation of the efficacy of Pycnogenol® in idiopathic fibromyalgia (FM), over 4 weeks in comparison with the standard management (SM). METHODS A SM and a Pycnogenol®+SM group were formed. Pycnogenol® supplementation was used at the dose of 150 mg/day (4 weeks). The study considered the most important/frequent symptoms of FM. RESULTS Fifty patients with idiopathic fibromyalgia were included: 26 in the Pycnogenol® group and 24 served as controls. The two groups were comparable at inclusion. No other disease or condition was present. All subjects were otherwise healthy women (BMI<26), not using any drug. All subjects had an elevated level of oxidative stress (OS) at inclusion. All routine blood tests - and all inflammatory and rheumatic tests - were within the normal range at inclusion and at the end of the study. No safety or tolerability problems were observed. The percentage of patients using NSAIDs (non-steroidal anti-inflammatory drugs) as rescue medications in the observation period was significantly higher in the SM management group (P<0.05) in comparison with the supplement group. The percentage of patients using corticosteroids as rescue medication was significantly higher in the SM group (P<0.05). The percentage of subjects with the symptoms/complaints decreased significantly, considering each symptom, with Pycnogenol® after 4 weeks in comparison with the SM (P<0.05). CONCLUSIONS Pycnogenol® supplementation appears to control and reduce the intensity of common symptoms and complaints - especially pain-related - associated with FM. Pycnogenol® could be a 'soft', safe supplementation and prevention method to manage the symptoms of most of these patients, even for longer periods, reducing the need for drugs.
Collapse
Affiliation(s)
- Gianni Belcaro
- IRVINE3 Labs & San Valentino Vascular Screening Project, Department of Medical, Oral and Biotechnological Sciences, Ch-Pe University, Pescara, Italy - .,IA-PSS: International Agency for Pharma-Standard Supplements, Pescara, Italy -
| | - Shu Hu
- IRVINE3 Labs & San Valentino Vascular Screening Project, Department of Medical, Oral and Biotechnological Sciences, Ch-Pe University, Pescara, Italy.,IA-PSS: International Agency for Pharma-Standard Supplements, Pescara, Italy
| | - Maria R Cesarone
- IRVINE3 Labs & San Valentino Vascular Screening Project, Department of Medical, Oral and Biotechnological Sciences, Ch-Pe University, Pescara, Italy.,IA-PSS: International Agency for Pharma-Standard Supplements, Pescara, Italy
| | - Mark Dugall
- IRVINE3 Labs & San Valentino Vascular Screening Project, Department of Medical, Oral and Biotechnological Sciences, Ch-Pe University, Pescara, Italy
| | - Claudia Scipione
- IRVINE3 Labs & San Valentino Vascular Screening Project, Department of Medical, Oral and Biotechnological Sciences, Ch-Pe University, Pescara, Italy
| | - Valeria Scipione
- IRVINE3 Labs & San Valentino Vascular Screening Project, Department of Medical, Oral and Biotechnological Sciences, Ch-Pe University, Pescara, Italy
| | - Morio Hosoi
- IRVINE3 Labs & San Valentino Vascular Screening Project, Department of Medical, Oral and Biotechnological Sciences, Ch-Pe University, Pescara, Italy
| | - Andrea Ledda
- IRVINE3 Labs & San Valentino Vascular Screening Project, Department of Medical, Oral and Biotechnological Sciences, Ch-Pe University, Pescara, Italy
| | - Umberto Cornelli
- IRVINE3 Labs & San Valentino Vascular Screening Project, Department of Medical, Oral and Biotechnological Sciences, Ch-Pe University, Pescara, Italy
| | - Beatrice Feragalli
- IRVINE3 Labs & San Valentino Vascular Screening Project, Department of Medical, Oral and Biotechnological Sciences, Ch-Pe University, Pescara, Italy
| | - Roberto Cotellese
- IRVINE3 Labs & San Valentino Vascular Screening Project, Department of Medical, Oral and Biotechnological Sciences, Ch-Pe University, Pescara, Italy
| |
Collapse
|
27
|
Morio H, Cesarone MR, Belcaro G, Feragalli B, Cotellese R, Hu S, Dugall M, Maione C, Scipione V, Scipione C, Riva A, Petrangolini G, Togni S. Supplementation with a new food grade delivery system of Boswellia and Centella in the intervertebral discs registry: the Sager study. Panminerva Med 2020; 64:48-55. [PMID: 32894920 DOI: 10.23736/s0031-0808.20.04028-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND The aim of this registry study was to investigate the potential of a new food-grade formulation of the association of Boswellia serrata and Centella asiatica extracts (Boswellia/Centella Phytosome, [BCP]) in combination with standard management (SM) to produce a faster re-expansion of the intervertebral disks in symptomatic subjects with "flattened" disks in the lower spine, due to wrong posture and compression after repeated trauma. METHODS The study was designed as a 3-6 months pilot registry. Three groups of subjects were comparable for characteristics and symptoms at baseline: SM+BCP; SM; SM+glucosamine. RESULTS No side effects were observed. Regarding target measurements at 3 and 6 months, height increased in the BCP group vs. the other two groups. The total spine length improved in the BCP group (P<0.05); in particular at 6 months the increase was doubled with BCP. SM was effective in producing elongation but the association with BCP made spinal elongation faster, more effective, with a better expansion of the intervertebral disks. Regarding ultrasound measurements, BCP was able to significantly ameliorate the posterior disk space (P<0.05) and decreased disk density more than the other groups of the study. Signs/symptoms and mobility were improved with BCP (P<0.05), while rescue medications decreased. The loss of working days was reduced with all managements (significantly more in BCP group than in the other two). CONCLUSIONS The relative effects on spinal elongation, disk space, signs/symptoms of BCP appeared to double the efficacy of SM, improving symptoms associated to a very good tolerability of BCP.
Collapse
Affiliation(s)
- Hosoi Morio
- Irvine3 Labs, Pescara, Italy.,Department SMO Biotec, Chieti-Pescara University, Pescara, Italy.,IAPSS, Pescara, Italy
| | - Maria R Cesarone
- Irvine3 Labs, Pescara, Italy.,Department SMO Biotec, Chieti-Pescara University, Pescara, Italy.,IAPSS, Pescara, Italy
| | - Gianni Belcaro
- Irvine3 Labs, Pescara, Italy - .,Department SMO Biotec, Chieti-Pescara University, Pescara, Italy.,IAPSS, Pescara, Italy
| | - Beatrice Feragalli
- Irvine3 Labs, Pescara, Italy.,Department SMO Biotec, Chieti-Pescara University, Pescara, Italy
| | - Roberto Cotellese
- Irvine3 Labs, Pescara, Italy.,Department SMO Biotec, Chieti-Pescara University, Pescara, Italy
| | - Shu Hu
- Irvine3 Labs, Pescara, Italy.,Department SMO Biotec, Chieti-Pescara University, Pescara, Italy.,IAPSS, Pescara, Italy
| | - Mark Dugall
- Irvine3 Labs, Pescara, Italy.,Department SMO Biotec, Chieti-Pescara University, Pescara, Italy.,IAPSS, Pescara, Italy
| | - Claudia Maione
- Irvine3 Labs, Pescara, Italy.,Department SMO Biotec, Chieti-Pescara University, Pescara, Italy.,IAPSS, Pescara, Italy
| | - Valeria Scipione
- Irvine3 Labs, Pescara, Italy.,Department SMO Biotec, Chieti-Pescara University, Pescara, Italy.,IAPSS, Pescara, Italy
| | - Claudia Scipione
- Irvine3 Labs, Pescara, Italy.,Department SMO Biotec, Chieti-Pescara University, Pescara, Italy.,IAPSS, Pescara, Italy
| | | | | | | |
Collapse
|
28
|
Ledda A, Hosoi M, Cesarone MR, Dugall M, Hu S, Belcaro G, Maione C, Cotellese R, Feragalli B, Scipione V, Scipione C. Exploring the concept of vigor and dys-vigor in men of 50-65 years: effects of Robuvit®. Panminerva Med 2020; 62:131-134. [DOI: 10.23736/s0031-0808.19.03795-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
29
|
Cesarone MR, Belcaro G, Scipione C, Scipione V, Dugall M, Hu S, Cotellese R, Feragalli B, Ledda A. Prevention of vaginal dryness in perimenopausal women. Supplementation with Lady Prelox®. ACTA ACUST UNITED AC 2020; 71:434-441. [PMID: 32064827 DOI: 10.23736/s0026-4784.19.04466-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND The aim of this pilot registry study was to use a standardized supplement (Lady Prelox®, Horphag Research) - including Pycnogenol®, l-arginine, L-citrulline and rose hip extract - to improve signs and symptoms associated with vaginal dryness in pre and post-menopausal healthy women. A group of women used only a standard management (SM) and a second group added Lady Prelox®. METHODS Four groups of women were included in the study. 34 pre-menopausal and 38 post-menopausal women took Lady Prelox®, four tablets daily for 8 weeks and 33 pre-menopausal women and 35 post-menopausal women served as controls. RESULTS No safety problems were observed with the supplement that was well tolerated. The subgroups of controls and supplemented subjects were comparable in both the pre- and post-menopausal groups. Among pre-menopausal women, results of the female sexual function index (FSFI) were significantly improved with the supplement in comparison with the control subjects' group (P<0.05). The results of the FSFI questionnaire for post-menopausal women indicated a significant improvement at 8 weeks with Lady Prelox® (P<0.05) in comparison with controls. Preclinical items (vaginal dryness, pain/discomfort during intercourse, mucus, minimal infections, presence of candida and oxidative stress) were significantly improved (P<0.05) with Lady Prelox®) in comparison to minimal changes with the SM group. These measurements included all women. CONCLUSIONS The effects of the supplementation with Lady Prelox® on vaginal dryness were significant. The supplement was well accepted and revealed no side effects or tolerability problems. Further studies are evaluating the effects of Lady Prelox® on other aspects of the menopausal transition that may alter the quality of life of most women in advanced age. A gentle approach with suitable dietary supplementation, represents a promising option for addressing common challenges that women experience in such conditions.
Collapse
Affiliation(s)
- Maria R Cesarone
- IRVINE3 Labs & Pap/Pea Screening Project and the International Irvine Network, Pescara, Italy.,IAAPS, International Agency for Pharma Standard Supplements, Chieti, Italy
| | - Gianni Belcaro
- IRVINE3 Labs & Pap/Pea Screening Project and the International Irvine Network, Pescara, Italy - .,IAAPS, International Agency for Pharma Standard Supplements, Chieti, Italy
| | - Claudia Scipione
- IRVINE3 Labs & Pap/Pea Screening Project and the International Irvine Network, Pescara, Italy.,IAAPS, International Agency for Pharma Standard Supplements, Chieti, Italy
| | - Valeria Scipione
- IRVINE3 Labs & Pap/Pea Screening Project and the International Irvine Network, Pescara, Italy.,IAAPS, International Agency for Pharma Standard Supplements, Chieti, Italy
| | - Mark Dugall
- IRVINE3 Labs & Pap/Pea Screening Project and the International Irvine Network, Pescara, Italy.,IAAPS, International Agency for Pharma Standard Supplements, Chieti, Italy
| | - Shu Hu
- Department of Medical, Oral Sciences and Biotechnologies, G. D'Annunzio University, Pescara, Italy
| | - Roberto Cotellese
- Department of Medical, Oral Sciences and Biotechnologies, G. D'Annunzio University, Pescara, Italy
| | - Beatrice Feragalli
- IRVINE3 Labs & Pap/Pea Screening Project and the International Irvine Network, Pescara, Italy.,IAAPS, International Agency for Pharma Standard Supplements, Chieti, Italy
| | - Andrea Ledda
- IRVINE3 Labs & Pap/Pea Screening Project and the International Irvine Network, Pescara, Italy.,IAAPS, International Agency for Pharma Standard Supplements, Chieti, Italy
| |
Collapse
|
30
|
Belcaro G, Cesarone MR, Scipione V, Scipione C, Dugall M, Hu S, Hosoi M, Cotellese R, Olivieri N, Feragalli B, Ledda A. Fatigue due to mild heart failure: effects of Robuvit® in a concept, pilot registry study. Minerva Cardioangiol 2020; 68:216-223. [DOI: 10.23736/s0026-4725.19.05029-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
31
|
Hu S, Belcaro G, Cesarone MR, Scipione C, Scipione V, Hosoi M, Cornelli U, Pellegrini L, Dugall M, Feragalli B, Cotellese R. Hangover and fatigue: effects of Robuvit® supplementation. A pilot registry study. Minerva Cardioangiol 2020; 68:203-208. [DOI: 10.23736/s0026-4725.19.05028-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
32
|
Cesarone MR, Belcaro G, Corsi M, Scipione C, Scipione V, Hu S, Hosoi M, Ledda A, Feragalli B, Cotellese R. Supplementary management with Pycnogenol® in patients with lupus vasculitis in remission phases: a pilot, concept registry study. Minerva Cardioangiol 2020; 68:146-152. [PMID: 32429631 DOI: 10.23736/s0026-4725.19.05027-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND The aim of this pilot study was the supplementary management of minimal, residual symptoms of systemic Lupus (SLE) with vasculitis (LV) in remission phases, using a natural, anti-inflammatory, antioxidant agent (Pycnogenol®) extracted from French maritime pine bark. Pycnogenol® has a significant clinical anti-inflammatory activity; it is a standardized supplement with a high-safety profile. METHODS Subjects with Lupus vasculitis were included in the study. The standard management (SM) was used in all subjects for 8 weeks; one group added Pycnogenol® (150 mg/day) to SM. RESULTS The two groups completing 8 weeks were comparable at baseline with 12 subjects managed with SM and 14 subjects supplemented with Pycnogenol®. No side effects due to Pycnogenol® were observed; Pycnogenol® was associated with an optimal tolerability. The proportion of patients with photosensitivity, oral ulcers, renal-associated hematuria (minimal), leukopenia, lymphopenia, thrombocytopenia, positive anti-DNA and positive antiphospolipids tests were significantly lower in the Pycnogenol® group (P<0.05) at 8 weeks in comparison with controls. No difference in activity between SM and supplementation was observed for rash, serositis, anemia, neurological symptoms (all mild at inclusion) and anti-Smith. Considering additional clinical parameters such as the need for corticosteroids, peripheral ischemia, oxidative stress, the effects of Pycnogenol® appeared to be superior to SM alone (P<0.05). The decrease in oxidative stress was significantly higher with Pycnogenol® (P<0.05) compared to SM. This is particularly interesting as it has not been observed before in LV. Considering microvascular parameters, the number of subjects with 'cold' hypoperfused thermographic areas was significantly lower in the supplement group (P<0.05) and distal flux (laser Doppler) was higher with the supplement (P<0.05) at 8 weeks. CONCLUSIONS This pilot registry indicates that Pycnogenol® can be safely used in subjects with LV with mild symptoms (in remission) possibly avoiding some drug treatments that may cause side effects. A larger study in progress is evaluating the effects of Pycnogenol® on recurrent symptoms in subjects in remission.
Collapse
Affiliation(s)
- Maria R Cesarone
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, Pescara, Italy.,IAAPS, International Agency For Pharma Standard Supplements, Pescara, Italy
| | - Gianni Belcaro
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, Pescara, Italy - .,IAAPS, International Agency For Pharma Standard Supplements, Pescara, Italy
| | - Marcello Corsi
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, Pescara, Italy.,IAAPS, International Agency For Pharma Standard Supplements, Pescara, Italy
| | - Claudia Scipione
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, Pescara, Italy.,IAAPS, International Agency For Pharma Standard Supplements, Pescara, Italy
| | - Valeria Scipione
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, Pescara, Italy.,IAAPS, International Agency For Pharma Standard Supplements, Pescara, Italy
| | - Shu Hu
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, Pescara, Italy.,IAAPS, International Agency For Pharma Standard Supplements, Pescara, Italy
| | - Morio Hosoi
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, Pescara, Italy.,IAAPS, International Agency For Pharma Standard Supplements, Pescara, Italy
| | - Andrea Ledda
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, Pescara, Italy.,IAAPS, International Agency For Pharma Standard Supplements, Pescara, Italy
| | - Beatrice Feragalli
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, Pescara, Italy.,IAAPS, International Agency For Pharma Standard Supplements, Pescara, Italy
| | - Roberto Cotellese
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, Pescara, Italy.,IAAPS, International Agency For Pharma Standard Supplements, Pescara, Italy
| |
Collapse
|
33
|
Cesarone MR, Belcaro G, Hosoi M, Ledda A, Feragalli B, Maione C, Scipione C, Scipione V, Cotellese R, Hu S. Supplementary management with Pycnogenol® in Parkinson's disease to prevent cognitive impairment. J Neurosurg Sci 2020; 64:258-262. [PMID: 31957998 DOI: 10.23736/s0390-5616.19.04839-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
BACKGROUND The aim of this registry study in patients with Parkinson's Disease (PD) in treatment, was to evaluate the effects of Pycnogenol® supplementation on some accessory symptoms and cognitive functions (COFU). METHODS The registry included 43 PD patients who had been diagnosed at least one year before the start of the study. The PD condition was considered mild, with minimal progression. The management for these patients was a monotherapy using carbidopa/levodopa (standard management; SM). Supplementary Pycnogenol® was used at 150 mg/day for 4 weeks. The neurological management was not affected. RESULTS Tolerability and safety were very good; the two registry groups were comparable with comparable symptoms at baseline. The most disabling symptoms were considered tremor, bradychinesia, alterations in COFU, rigidity and speech changes. All symptoms were rated as mild-to-moderate. After 4 weeks, these target symptoms were significantly attenuated with the supplement in comparison with the SM only (P<0.05). Particularly the COFU score was significantly higher (P<0.05) with the supplement. No interference between the main neurological management and the supplement was observed. Oxidative stress (plasma free radicals), high in both registry groups at inclusion, was significantly lower in the supplement group at 4 weeks (P<0.05). The main PD-associated items (cognitive aspects, motory and postural aspects) considered the most common and disturbing problems were evaluated and scored (0 to 4) with a visual scale line. At 4 weeks, the scores for all items were lower in the supplement group in comparison with the control, SM group. Peripheral edema was present in all patients at inclusion. The edema was minimal at inclusion (at the ankle-foot level with pretibial extension) and present in all subjects. It changed in two SM subjects and was still present at 4 weeks in 19 out 22 of the SM patients. In the supplemented patients, edema (present at inclusion in all subjects), was visible in 4 subjects out of 21 (19%) at 4 weeks. CONCLUSIONS Pycnogenol® supplementation may help in selected patients with PD - under stable neurological treatment - to improve some signs and symptoms and some aspects associated with COFU. Studies are in progress on a larger population sample and with new evaluation methods.
Collapse
Affiliation(s)
- Maria R Cesarone
- Irvine3 Labs & San Valentino Vascular Screening Project, Chieti, Italy.,Department of Medical Oral Biotechnology Sciences, D'Annunzio University, IA-PSS (International Agency for Pharma-Standard Supplements), Pescara, Italy
| | - Gianni Belcaro
- Irvine3 Labs & San Valentino Vascular Screening Project, Chieti, Italy - .,Department of Medical Oral Biotechnology Sciences, D'Annunzio University, IA-PSS (International Agency for Pharma-Standard Supplements), Pescara, Italy
| | - Morio Hosoi
- Irvine3 Labs & San Valentino Vascular Screening Project, Chieti, Italy.,Department of Medical Oral Biotechnology Sciences, D'Annunzio University, IA-PSS (International Agency for Pharma-Standard Supplements), Pescara, Italy
| | - Andrea Ledda
- Irvine3 Labs & San Valentino Vascular Screening Project, Chieti, Italy.,Department of Medical Oral Biotechnology Sciences, D'Annunzio University, IA-PSS (International Agency for Pharma-Standard Supplements), Pescara, Italy
| | - Beatrice Feragalli
- Department of Medical Oral Biotechnology Sciences, D'Annunzio University, IA-PSS (International Agency for Pharma-Standard Supplements), Pescara, Italy
| | - Claudia Maione
- Irvine3 Labs & San Valentino Vascular Screening Project, Chieti, Italy
| | - Claudia Scipione
- Irvine3 Labs & San Valentino Vascular Screening Project, Chieti, Italy
| | - Valeria Scipione
- Irvine3 Labs & San Valentino Vascular Screening Project, Chieti, Italy
| | - Roberto Cotellese
- Department of Medical Oral Biotechnology Sciences, D'Annunzio University, IA-PSS (International Agency for Pharma-Standard Supplements), Pescara, Italy
| | - Shuh Hu
- Irvine3 Labs & San Valentino Vascular Screening Project, Chieti, Italy.,Department of Medical Oral Biotechnology Sciences, D'Annunzio University, IA-PSS (International Agency for Pharma-Standard Supplements), Pescara, Italy
| |
Collapse
|
34
|
Belcaro G, Cesarone MR, Scipione C, Scipione V, Dugall M, Hu S, Feragalli B, Luzzi R, Hosoi M, Maione C, Cotellese R. Pycnogenol®+Centellicum®, post-stent evaluation: prevention of neointima and plaque re-growth. Minerva Cardioangiol 2019; 67:450-455. [PMID: 31850725 DOI: 10.23736/s0026-4725.19.05048-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND The aim of this study was to evaluate the regrowth and progression of within-stent neointima after stenting as a model of accelerated atherosclerosis and the potential effects of the combination Pycnogenol® and Centellicum® in 12 months' follow-up. METHODS Progression was defined as the passage from one arterial risk class to next, more advanced risk class in 12 months of follow-up. Each class corresponds to a different risk of cardiovascular events and progression. Three management groups were formed, treated with either standard management (SM), Pycnogenol® 150 mg/day, or a combination of Pycnogenol® 150 mg/day and Centellicum® 450 mg/day. RESULTS No side effects or tolerability problems were observed. 82 subjects with stented arteries in class 2 were evaluated for the passage into class 3 over 12 months. This group included 82 subjects; there were no dropouts. The management subgroups were comparable at baseline. At 12 months 66.7% of subjects in the SM subgroup progressed to class 3, versus 10.7% in the Pycnogenol® group; progression was seen in 6.7% (P<0.05) of subjects supplemented with the combination. In the second section of the registry study (78 subjects with stented arteries in class 3) we evaluated the percentage of patients passing into class 4. At 12 months 53.6% of subjects using the SM progressed versus 26.9% in the subgroup using Pycnogenol® (P<0.05) and 11.5% in the Pycnogenol®+Centellicum® group (P<0.05). Across all 160 subjects in the three management groups, progression of the stented artery at 12 months was seen in 59.6% of subjects in the SM group versus 18.5% (P<0.05) in the group managed with Pycnogenol® only. The Pycnogenol®+Centellicum® combination further decreased progression down to 8.9% (P<0.05). Oxidative stress was significantly reduced (P<0.05) in the two supplement groups. CONCLUSIONS In conclusion, the combination Pycnogenol®+Centellicum® appears to reduce the rate of progression of the neointima after stenting.
Collapse
Affiliation(s)
- Gianni Belcaro
- Irvine3 Labs, Department of Medical and Oral Sciences, and Biotechnologies, G. D'Annunzio University, Pescara, Italy -
- International Agency for Pharma-Standard Supplements (IA-PSS), Geneva, Switzerland -
| | - Maria R Cesarone
- Irvine3 Labs, Department of Medical and Oral Sciences, and Biotechnologies, G. D'Annunzio University, Pescara, Italy
- International Agency for Pharma-Standard Supplements (IA-PSS), Geneva, Switzerland
| | - Claudia Scipione
- Irvine3 Labs, Department of Medical and Oral Sciences, and Biotechnologies, G. D'Annunzio University, Pescara, Italy
- International Agency for Pharma-Standard Supplements (IA-PSS), Geneva, Switzerland
| | - Valeria Scipione
- Irvine3 Labs, Department of Medical and Oral Sciences, and Biotechnologies, G. D'Annunzio University, Pescara, Italy
- International Agency for Pharma-Standard Supplements (IA-PSS), Geneva, Switzerland
| | - Mark Dugall
- Irvine3 Labs, Department of Medical and Oral Sciences, and Biotechnologies, G. D'Annunzio University, Pescara, Italy
- International Agency for Pharma-Standard Supplements (IA-PSS), Geneva, Switzerland
| | - Shu Hu
- Irvine3 Labs, Department of Medical and Oral Sciences, and Biotechnologies, G. D'Annunzio University, Pescara, Italy
- International Agency for Pharma-Standard Supplements (IA-PSS), Geneva, Switzerland
| | - Beatrice Feragalli
- Irvine3 Labs, Department of Medical and Oral Sciences, and Biotechnologies, G. D'Annunzio University, Pescara, Italy
- International Agency for Pharma-Standard Supplements (IA-PSS), Geneva, Switzerland
| | - Roberta Luzzi
- Irvine3 Labs, Department of Medical and Oral Sciences, and Biotechnologies, G. D'Annunzio University, Pescara, Italy
- International Agency for Pharma-Standard Supplements (IA-PSS), Geneva, Switzerland
| | - Morio Hosoi
- Irvine3 Labs, Department of Medical and Oral Sciences, and Biotechnologies, G. D'Annunzio University, Pescara, Italy
- International Agency for Pharma-Standard Supplements (IA-PSS), Geneva, Switzerland
| | - Claudia Maione
- Irvine3 Labs, Department of Medical and Oral Sciences, and Biotechnologies, G. D'Annunzio University, Pescara, Italy
- International Agency for Pharma-Standard Supplements (IA-PSS), Geneva, Switzerland
| | - Roberto Cotellese
- Irvine3 Labs, Department of Medical and Oral Sciences, and Biotechnologies, G. D'Annunzio University, Pescara, Italy
- International Agency for Pharma-Standard Supplements (IA-PSS), Geneva, Switzerland
| |
Collapse
|
35
|
Cesarone MR, Dugall M, Hu S, Belcaro G, Hosoi M, Scipione V, Scipione C, Cotellese R. Episodic primary migraine headache: supplementary prophylaxis with Pycnogenol® prevents attacks and controls oxidative stress. Panminerva Med 2019; 62:102-108. [PMID: 31670494 DOI: 10.23736/s0031-0808.19.03745-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND This registry study investigated the supplement Pycnogenol® on migraine headache attacks and oxidative stress in otherwise healthy subjects with migraine and moderate headache (MH). METHODS To manage MH, these subjects used only a few drugs (antiemetics, analgesics on demand) and lifestyle changes; only very occasionally they used other, more specific products such as triptans. Study groups: one group used only standard management (SM), basically, management on demand. Oral magnesium and riboflavin (vitamin B2) were used with lipoic acid as they are considered useful to improve MH. Another group used the supplement Pycnogenol® (150 mg/day for 8 weeks) in addition to SM. These two groups were compared to a third (non-parallel, observational) group using topiramate (50 mg/day). If needed, subjects were allowed to use rescue medications. RESULTS Forty-six subjects were included in the study. Twenty-two used the standard management and 24 were supplemented with Pycnogenol® in association with SM. In addition, 21 subjects were treated with topiramate. Safety with Pycnogenol® was very good. The two main management groups and the third non-parallel group had comparable baseline characteristics. The number of migraine attacks were significantly reduced during the observation period with Pycnogenol® (P<0.05) in comparison with SM. Supplementation was more effective in reducing the use of rescue medications (P<0.05) including analgesics compared to SM. At 8 weeks, the pain score was lower with Pycnogenol in comparison with SM (P<0.05). The working incapacity was significantly lower with Pycnogenol® than in the SM group (P<0.05). The number of migraine attacks was lower with topiramate compared to SM. Pain score, working incapacity and use of rescue medication were lower with topiramate than in SM. However, adverse effects with topiramate, included paresthesia, fatigue, dizziness and nausea even at low dosages complicated management. Some 50% of these side effects require a form of further treatment including medications. Oxidative stress: all included subjects had high oxidative stress at baseline. At 8 weeks, the level of plasma free radicals was significantly lowered with Pycnogenol® (P<0.05), but not in the SM or topiramate group. CONCLUSIONS Pycnogenol® used as prophylaxis appears to reduce pain and the number and severity of symptoms in MH in parallel with a reduction of oxidative stress.
Collapse
Affiliation(s)
- Maria R Cesarone
- IRVINE3 Labs, Department of Medical Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
| | - Mark Dugall
- IRVINE3 Labs, Department of Medical Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
| | - Shu Hu
- IRVINE3 Labs, Department of Medical Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
| | - Gianni Belcaro
- IRVINE3 Labs, Department of Medical Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy -
| | - Morio Hosoi
- IRVINE3 Labs, Department of Medical Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
| | - Valeria Scipione
- IRVINE3 Labs, Department of Medical Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
| | - Claudia Scipione
- IRVINE3 Labs, Department of Medical Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy
| | - Roberto Cotellese
- School of Specialization, General Surgery, Chieti-Pescara University, IAPSS, Pescara, Italy
| |
Collapse
|
36
|
Belcaro G, Cesarone MR, Scipione C, Scipione V, Dugall M, Shu H, Peterzan P, Corsi M, Luzzi R, Hosoi M, Feragalli B, Cotellese R. Delayed progression of atherosclerosis and cardiovascular events in asymptomatic patients with atherosclerotic plaques: 3-year prevention with the supplementation with Pycnogenol®+Centellicum®. Minerva Cardioangiol 2019; 68:15-21. [PMID: 31625707 DOI: 10.23736/s0026-4725.19.05051-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND The aim of this study was the evaluation of the progression of atherosclerosis and the occurrence of cardiovascular events in asymptomatic patients with atherosclerotic plaques (Class IV and V) and arterial wall atherosclerotic lesions and intima-media thickening (IMT). METHODS Progression of atherosclerotic lesions, oxidative stress and IMT were measured in a 3-year concept, pilot registry study. All subjects were followed with standard management (SM) - including diet and exercise - to control cardiovascular risk factors.The target measurements were: the rate of progression of the atherosclerotic lesions (the passage of subjects from one atherosclerotic class to the next class); the occurrence of "hard" cardiovascular events (i.e. myocardial infarction or strokes; angina was not considered a "hard" event). The study included 3 groups: 1) SM): 2) subjects using cardioaspirin (100 mg/day) and SM; 3) subjects following SM, taking cardioaspirin and supplemented with Pycnogenol® (150 mg/day)+Centellicum® (450 mg/day). RESULTS The groups were comparable for age and baseline evaluations. 54 subjects completed the 3 year study with standard management only, 74 with aspirin and 56 with aspirin and Pycnogenol®+Centellicum®. The BMI of all subjects was <26. No side effects and no tolerability problems were observed with the supplements. Progression was defined by the passage of the atherosclerotic lesions from one class to the next more advanced class. Progression in the supplement group was observed in 5.3% of the subjects in comparison with a progression >20% in the other groups (P<0.05). In comparison with the SM group and the cardioaspirin group the rate of 'hard' cardiovascular events, requiring hospital admissions were <4% with the combined supplement in comparison with a value >12% in the other two groups (22.22% event rate in the SM group). The reduction produced by the aspirin only was significantly lower (P<0.05) in comparison with supplemented patients. Antiplatelet management appears to reduce a significant number of events (P<0.05) without a real effect on progression of atherosclerotic lesions. The additional parameters of carotid IMT and oxidative stress were also lower (P<0.05) with the supplements. CONCLUSIONS In conclusion, this study indicates that the combined supplementation with Pycnogenol®+Centelicum® appears to control both the progression of atherosclerosis and the occurrence of cardiovascular events in this 3 year study. Larger studies, in a wider population with more complex and less standardized conditions may be needed.
Collapse
Affiliation(s)
- Gianni Belcaro
- Irvine3 Labs & San Valentino Vascular Screening Project, Chieti-Pescara University, Chieti, Italy - .,International Agency for Pharma-Standard Supplements (IA-PSS), Pescara, Italy - .,DSMO-Biotec, Chieti-Pescara University, Chieti, Italy -
| | - Maria R Cesarone
- Irvine3 Labs & San Valentino Vascular Screening Project, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma-Standard Supplements (IA-PSS), Pescara, Italy.,DSMO-Biotec, Chieti-Pescara University, Chieti, Italy
| | - Claudia Scipione
- Irvine3 Labs & San Valentino Vascular Screening Project, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma-Standard Supplements (IA-PSS), Pescara, Italy
| | - Valeria Scipione
- Irvine3 Labs & San Valentino Vascular Screening Project, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma-Standard Supplements (IA-PSS), Pescara, Italy
| | - Mark Dugall
- Irvine3 Labs & San Valentino Vascular Screening Project, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma-Standard Supplements (IA-PSS), Pescara, Italy
| | - Hu Shu
- Irvine3 Labs & San Valentino Vascular Screening Project, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma-Standard Supplements (IA-PSS), Pescara, Italy
| | - Paula Peterzan
- Irvine3 Labs & San Valentino Vascular Screening Project, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma-Standard Supplements (IA-PSS), Pescara, Italy
| | - Marcello Corsi
- Irvine3 Labs & San Valentino Vascular Screening Project, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma-Standard Supplements (IA-PSS), Pescara, Italy
| | - Roberta Luzzi
- Irvine3 Labs & San Valentino Vascular Screening Project, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma-Standard Supplements (IA-PSS), Pescara, Italy
| | - Morio Hosoi
- Irvine3 Labs & San Valentino Vascular Screening Project, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma-Standard Supplements (IA-PSS), Pescara, Italy
| | | | | |
Collapse
|
37
|
Cesarone MR, Belcaro G, Hu S, Dugall M, Hosoi M, Ledda A, Feragalli B, Maione C, Cotellese R. Supplementary prevention and management of asthma with quercetin phytosome: a pilot registry. Minerva Med 2019; 110:524-529. [PMID: 31578841 DOI: 10.23736/s0026-4806.19.06319-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND In association with standard management, natural pharmaceutical standard (PS) supplements may play an important role in managing and preventing mild-to-moderate symptoms of asthma, a significant health issue that impacts patients and the healthcare system. Quercetin is a natural flavonoid with important biological properties (anti-inflammatory, antihistamine and anti-oxidative actions). METHODS In this pilot registry, we evaluated the effects of quercetin formulated with the Phytosome® delivery system (Quercefit™, QFit)+standard management (SM) in otherwise healthy subjects with mild-moderate asthmatic attacks and rhinitis. Subjects used either QFit 1 or 2 tabs/day in association with SM or SM only (control group). After 30 days of management, we evaluated the presence of the main signs/symptoms of asthma according to the GINA classification system also considering the need of rescue medication, nasal drops, the use of inhalers, the rhinitis score and oxidative stress. RESULTS QFit+SM showed superior results compared with SM alone in controlling, preventing and reducing daily and night symptoms, in maintaining higher peak expiratory flow (PEF) and in decreasing PEF variability. The supplementary use of QFit improved additional measures of asthma management, decreasing the use of inhalers, nasal drops, rescue medications and improving the rhinitis score. QFit produced a significantly more evident reduction in oxidative stress compared with SM; Qfit showed a very good safety profile. CONCLUSIONS This preliminary supplement, concept registry shows a potential protective and preventive effect of quercetin on attacks frequency and in controlling the most common signs/symptoms of asthma in the milder cases of the disease.
Collapse
Affiliation(s)
- Maria R Cesarone
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, Chieti, Italy
| | - Gianni Belcaro
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, Chieti, Italy -
| | - Shu Hu
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, Chieti, Italy
| | - Mark Dugall
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, Chieti, Italy
| | - Morio Hosoi
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, Chieti, Italy
| | - Andrea Ledda
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, Chieti, Italy
| | - Beatrice Feragalli
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, Chieti, Italy
| | - Claudia Maione
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, Chieti, Italy
| | - Roberto Cotellese
- IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, Chieti, Italy
| |
Collapse
|
38
|
Belcaro G, Dugall M, Bradford HD, Cesarone MR, Feragalli B, Gizzi C, Cotellese R, Hu S, Rodriguez P, Hosoi M. Recurrent retinal vein thrombosis: prevention with Aspirin, Pycnogenol®, ticlopidine, or sulodexide. Minerva Cardioangiol 2019; 67:109-114. [PMID: 30964246 DOI: 10.23736/s0026-4725.19.04891-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND The aim of this study is to evaluate the use of Aspirin, Pycnogenol®, ticlopidine, and sulodexide to reduce the incidence of new RTV (retinal vein thrombosis) after a first episode. Pycnogenol® is an anti-inflammatory, anti-edema, mild antiplatelet-antithrombotic agent. METHODS The registry study evaluated the number of repeated episodes of RVT in 12 months. Possible managements were: standard management (SM); SM + Aspirin (100 mg/once day; if there were no tolerability problems); SM + Pycnogenol (100 mg/day); SM and ticlopidine (200 mg/day); SM + sulodexide (500 ULS/day). The number of subjects age and sex, distribution, the percent of smokers, the vision were comparable at inclusion. RESULTS 307 subjects completed the study, 44 in the SM group, 90 in the Pycnogenol® group, 90 in the aspirin group, 45 in the ticlopidine group and 38 in the sulodexide group. At 12 months, recurrent RVT was documented in 22.7% of controls (SM), 3.3% of Pycnogenol® subjects (P<0.05 vs. SM; 19.4% difference). There were RVTs in 15.5% subjects using Aspirin (-7.2% vs. SM). Ticlopidine also reduced (P<0.05) the incidence of RVT in comparison with SM (-9.1%). Sulodexide reduced the occurrence of new RVT (-9.5% vs. SM). Edema was better controlled with the supplement than with all other treatments (P<0.05) (edema present in only 5.5% of the Pycnogenol® subjects). Pycnogenol® had a very good tolerability and safety profile (no patient had to stop treatment). CONCLUSIONS Pycnogenol® is the only product able to control edema and this may reduce the incidence of recurrent RVT. This retrospective registry indicates that Aspirin, Pycnogenol®, ticlopidine an sulodexide reduce recurrent RVT without side effects. Larger studies should be planned to involve a wider range of conditions, diseases and risk factors associated with RVT and to its recurrence.
Collapse
Affiliation(s)
- Gianni Belcaro
- Irvine3 Labs, Circulation Sciences, Chieti-Pescara University, Pescara, Italy - .,IAPSS International Agency for Pharma Standard Supplements, Geneva, Switzerland -
| | - Mark Dugall
- Irvine3 Labs, Circulation Sciences, Chieti-Pescara University, Pescara, Italy.,IAPSS International Agency for Pharma Standard Supplements, Geneva, Switzerland
| | - Hugh D Bradford
- Irvine3 Labs, Circulation Sciences, Chieti-Pescara University, Pescara, Italy.,IAPSS International Agency for Pharma Standard Supplements, Geneva, Switzerland
| | - Maria R Cesarone
- Irvine3 Labs, Circulation Sciences, Chieti-Pescara University, Pescara, Italy.,IAPSS International Agency for Pharma Standard Supplements, Geneva, Switzerland
| | - Beatrice Feragalli
- Irvine3 Labs, Circulation Sciences, Chieti-Pescara University, Pescara, Italy.,IAPSS International Agency for Pharma Standard Supplements, Geneva, Switzerland
| | - Corrado Gizzi
- Irvine3 Labs, Circulation Sciences, Chieti-Pescara University, Pescara, Italy.,IAPSS International Agency for Pharma Standard Supplements, Geneva, Switzerland
| | - Roberto Cotellese
- Irvine3 Labs, Circulation Sciences, Chieti-Pescara University, Pescara, Italy.,IAPSS International Agency for Pharma Standard Supplements, Geneva, Switzerland
| | - Shu Hu
- Irvine3 Labs, Circulation Sciences, Chieti-Pescara University, Pescara, Italy.,IAPSS International Agency for Pharma Standard Supplements, Geneva, Switzerland
| | - Patrizia Rodriguez
- Irvine3 Labs, Circulation Sciences, Chieti-Pescara University, Pescara, Italy.,IAPSS International Agency for Pharma Standard Supplements, Geneva, Switzerland
| | - Morio Hosoi
- Irvine3 Labs, Circulation Sciences, Chieti-Pescara University, Pescara, Italy.,IAPSS International Agency for Pharma Standard Supplements, Geneva, Switzerland
| |
Collapse
|
39
|
Cesarone MR, Belcaro G, Agus GB, Ippolito E, Dugall M, Hosoi M, Corsi M, Cotellese R, Feragalli B, Scipione C, Scipione V, Maione C. Chronic venous insufficiency and venous microangiopathy: management with compression and Pycnogenol®. Minerva Cardioangiol 2019; 67:280-287. [DOI: 10.23736/s0026-4725.19.04948-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
40
|
Belcaro G, Cornelli U, Dugall M, Cotellese R, Feragalli B, Cesarone MR. Pycnogenol® prevents oxidative stress and side effects in patients with hypothyroidism during levothyroxine treatment. MINERVA ENDOCRINOL 2019; 44:199-204. [PMID: 31099529 DOI: 10.23736/s0391-1977.18.02821-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND In this study we aimed to evaluate the efficacy of Pycnogenol® supplementation in controlling oxidative stress levels and in reducing the frequency and severity of side effects of levothyroxine (LT4) treatment in patients who had recently started this therapy. METHODS The registry included 60 females affected by primary hypothyroidism with multi-nodular goiter. LT4 was administered at the dosage of 100 μg/day.The registry study included only subjects under initial treatment, and followed up for a period of at least 30 days. A group took 150 mg Pycnogenol® daily and another served as control. RESULTS The global occurrence of symptoms during the 30-day period was significantly lower with the supplement (P<0.05). CONCLUSIONS Pycnogenol® may represent a useful tool to reduce LT4- related side effects in patients treated with hormone replacement therapy for hypothyroidism.
Collapse
Affiliation(s)
- Gianni Belcaro
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy - .,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy -
| | - Umberto Cornelli
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Mark Dugall
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Roberto Cotellese
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Beatrice Feragalli
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Maria R Cesarone
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| |
Collapse
|
41
|
Feragalli B, Dugall M, Luzzi R, Ledda A, Hosoi M, Belcaro G, Cesarone MR. Pycnogenol®: supplementary management of symptomatic osteoarthritis with a patch. An observational registry study. MINERVA ENDOCRINOL 2019; 44:97-101. [PMID: 30561176 DOI: 10.23736/s0391-1977.18.02820-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND The aim of the present observational registry study was to evaluate the efficacy of a thin polycarbonate patch of Pycnogenol® in alleviating symptoms of knee arthrosis, in comparison to the standard management usually applied to treat osteoarthritis (OA). METHODS A total of 67 subjects were included in the registry: 34 formed the control group, and 33 entered the active management group in which the Pycnogenol® patch was used. Two Pycnogenol® patches were used every day for three weeks. Each patch contains 110 mg Pycnogenol®. All patients included in this registry suffered from osteoarthritis of the knee. RESULTS Results from this study show that Pycnogenol® patch allows faster improvement in OA symptoms, with a decrease in the use of non-steroidal anti-inflammatory drugs and other painkillers. Pycnogenol® patch significally reduced C reactive protein and ESR. CONCLUSIONS Pycnogenol® patch was effective in controlling mild to moderate pain and inflammations and its related symptoms in subjects with knee OA over a period of three weeks.
Collapse
Affiliation(s)
- Beatrice Feragalli
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Mark Dugall
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Roberta Luzzi
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Andrea Ledda
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Morio Hosoi
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Gianni Belcaro
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy - .,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Maria R Cesarone
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| |
Collapse
|
42
|
Belcaro G, Saggino A, Cornelli U, Luzzi R, Dugall M, Hosoi M, Feragalli B, Cesarone MR. Improvement in mood, oxidative stress, fatigue, and insomnia following supplementary management with Robuvit®. J Neurosurg Sci 2018; 62:423-427. [PMID: 29938480 DOI: 10.23736/s0390-5616.18.04384-9] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Oxidative stress (OS) plays a substantial role in inflammatory and neurodegenerative diseases, causing cellular damage and mitochondrial dysfunction. OS also contributes to aging and severe neural disorders such as Alzheimer's and Parkinson's diseases. Previous registries have documented a reduction in OS levels with Robuvit® (Horphag Research, Ltd.), an extract from wood of the French oak (Quercus robur) that provides a decrease of OS as well as relief from chronic fatigue syndrome. The aim of the present registry was to investigate the influence of Robuvit® on a group of subjects presenting with mood disorders, oxidative stress, fatigue, and insomnia. METHODS Forty patients were recruited from a selection of patients with high OS levels as assessed with the d-ROMs test. Twenty-two subjects formed the control group following the standard management plan. The remaining 18 subjects formed the Robuvit® supplementation group. They received three capsules of Robuvit® 100 mg per day, for 8 weeks. RESULTS Tolerability to the supplementation with Robuvit® was overall good, and no safety concerns were raised. Mood tests showed a significant general improvement in 13 out of 16 items of the BMIS (P<0.05) in the active treatment group. Oxidative stress levels decreased significantly with Robuvit® supplementation after 4 and 8 weeks. Fatigue and insomnia score were also significantly better in supplemented subjects (P<0.05). No changes were observed in controls. CONCLUSIONS The observed decrease in OS levels in our patients is probably the result of the antioxidative activity of Robuvit®, and, more precisely, of its active metabolites, the urolithins and ellagic acid.
Collapse
Affiliation(s)
- Gianni Belcaro
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy - .,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy -
| | - Aristide Saggino
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Umberto Cornelli
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Roberta Luzzi
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Mark Dugall
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Morio Hosoi
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Beatrice Feragalli
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Maria R Cesarone
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| |
Collapse
|
43
|
Hu S, Belcaro G, Ledda A, Corsi M, Cotellese R, Feragalli B, Hosoi M, Dugall M, Torino-Rodriguez P, Cesarone MR. Mononucleosis-related fatigue: supplementary management with Robuvit®. Minerva Pediatr 2018; 70:425-429. [DOI: 10.23736/s0026-4946.18.05213-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
44
|
Riva A, Corti A, Belcaro G, Cesarone MR, Dugall M, Vinciguerra G, Feragalli B, Zuccarini M, Eggenhoffner R, Giacomelli L. Interaction study between antiplatelet agents, anticoagulants, diabetic therapy and a novel delivery form of quercetin. Minerva Cardioangiol 2018; 67:79-83. [PMID: 30226032 DOI: 10.23736/s0026-4725.18.04795-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
BACKGROUND In this pilot non-interference clinical study we evaluated possible interactions between Quercetin Phytosome® (Quercefit™), an innovative delivery form of quercetin, and antiplatelet agents, anticoagulants, and anti-diabetic therapy in otherwise healthy subjects. METHODS Interaction with antiplatelet therapy was assessed through the bleeding time (BT) test in 30 patients treated with acetylsalicylic acid, ticlopidine or clopidogrel before and after 10 days of supplementation with Quercetin Phytosome®. Interaction with anticoagulants was evaluated by measuring the International Normalized Ratio (INR) in 20 patients using warfarin or dabigatran before and after 20 days of supplementation with Quercetin Phytosome®. Lastly, glycaemia and glycated hemoglobin were measured in 12 diabetic patients treated with metformin and restricted diet before and after 20 days of supplementation with Quercetin Phytosome®. RESULTS After 10 days of supplementation no significant difference was observed in mean BT in patients treated with acetylsalicylic acid, ticlopidine or clopidogrel at standard dosages. Similarly, after 20 days of supplementation, the INR level among patients assuming warfarin or dabigatran was not statistically different from baseline. Lastly, no statistically significant difference in mean levels of glycaemia and glycated hemoglobin was reported before and after 20 days of complementary administration of Quercetin Phytosome® in diabetic patients treated with metformin and restricted diet. CONCLUSIONS Quercetin Phytosome® does not alter the antiplatelet activity of the most common antiplatelet agents, has no impact on the INR values in stable patients treated with warfarin or dabigatran, and does not influence the metabolic control of diabetic patient treated with metformin.
Collapse
Affiliation(s)
| | | | - Gianni Belcaro
- IRVINE3 Vascular Lab, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, Chieti, Italy
| | - Maria R Cesarone
- IRVINE3 Vascular Lab, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, Chieti, Italy
| | - Mark Dugall
- IRVINE3 Vascular Lab, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, Chieti, Italy
| | | | - Beatrice Feragalli
- IRVINE3 Vascular Lab, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, Chieti, Italy
| | - Mariachiara Zuccarini
- IRVINE3 Vascular Lab, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, Chieti, Italy
| | - Roberto Eggenhoffner
- Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa, Italy
| | - Luca Giacomelli
- Polistudium SRL, Milan, Italy - .,Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa, Italy
| |
Collapse
|
45
|
Ledda A, Belcaro G, Feragalli B, Cornelli U, Dugall M, Corsi M, Cesarone MR. Benign prostatic hypertrophy: Pycnogenol® supplementation improves prostate symptoms and residual bladder volume. Minerva Med 2018; 109:280-284. [PMID: 29947491 DOI: 10.23736/s0026-4806.18.05572-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND The aim of this study was to evaluate the efficacy of Pycnogenol® supplementation in terms of safety and tolerability in the setting of preclinical or borderline, initial symptoms of benign prostatic hyperthrophy (BPH), in otherwise healthy subjects, using Pycnogenol® over a period of 60 days. METHODS Seventy-five healthy men with symptoms and signs of initial BPH were included. The subjects were divided into three groups: 1) control group using only the standard management (SM); 2) a group using SM plus Pycnogenol® 150 mg/day; 3) a group using standard pharmacological management. RESULTS BPH symptoms like emptying, frequency, intermittency, urgency, weak flow, straining, nocturia, were all significantly improved with Pycnogenol® (P<0.05) and the difference with both control groups was statistically significant (P<0.05). CONCLUSIONS Pycnogenol® may be an important option for self-management of BPH in otherwise healthy men.
Collapse
Affiliation(s)
- Andrea Ledda
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Gianni Belcaro
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy - .,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Beatrice Feragalli
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Umberto Cornelli
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Mark Dugall
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Marcello Corsi
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Maria R Cesarone
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| |
Collapse
|
46
|
Hu S, Belcaro G, Ledda A, Corsi M, Cotellese R, Feragalli B, Hosoi M, Dugall M, Torino-Rodriguez P, Cesarone MR. Behçet syndrome: effects of Pycnogenol® supplementation during regression phases. Minerva Cardioangiol 2018; 66:386-390. [PMID: 29975020 DOI: 10.23736/s0026-4725.18.04637-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND The aim of this comparative registry study was to evaluate the supplementation with Pycnogenol® in subjects with Behçet syndrome (BS) with symptoms impairing their quality of life despite being in a remitting phase of the disease. METHODS Thirty-four patients with a confirmed diagnosis of BS were divided into the control group (without supplement) or the active group, in this specific case using Pycnogenol® (Horphag Research LTD) supplement at the daily dose of 150 mg (50 mg tid) for 4 weeks. RESULTS All subjects receiving Pycnogenol® reported a significant decrease in symptoms, such as burning/pain due to dryness and ulcerations (P<0.05). In addition, Pycnogenol® showed important anti-inflammatory activity by decreasing ESR, leucocytosis and Pathergy Test response. CONCLUSIONS Pycnogenol® may be a useful supplementation for the management of BS.
Collapse
Affiliation(s)
- Shu Hu
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Gianni Belcaro
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy - .,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Andrea Ledda
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Marcello Corsi
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Roberto Cotellese
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Beatrice Feragalli
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Morio Hosoi
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Mark Dugall
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Patrizia Torino-Rodriguez
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Maria R Cesarone
- IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| |
Collapse
|
47
|
Belcaro G, Dugall M, Cotellese R, Feragalli B, Cianchetti E, Cesarone MR. Supplementation with Robuvit® in post-mastectomy post-radiation arm lymphedema. MINERVA CHIR 2018; 73:288-294. [PMID: 29911794 DOI: 10.23736/s0026-4733.18.07667-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Post-mastectomy lymphedema is one of the most significant, non-life-threatening complications following breast cancer surgery and radiotherapy. Post-mastectomy post-radiotherapy (PMPR) lymphedema is related to damages to lymphatics and/or veins during/after axillary surgery and radiotherapy. The management of this condition is very challenging; the comprehensive decongestive therapy (CTD), which combines physiotherapy, self-management, and hygiene, and is currently considered the standard management (SM). The aim of this registry study was to evaluate whether the supplementation with Robuvit® as a lymphedema controlling agent added to CTD over a 2-month period could be more effective than CTD alone. METHODS A group of 65 patients with PMPR lymphedema was included in this registry study and followed up for 2 months; 33 were treated with current SM only (control group), and 32 were also supplemented with 600 mg/day of Robuvit® (active treatment group). RESULTS At 1- and 2-month follow-up, the decrease in volume was significantly greater in the supplement group (P<0.05), with a final reduction in volume after two months of 654±21 mL (-19.82%) versus 433±23 mL (-12.81%) in the control group. A more significant decrease in skin thickness and symptoms was also observed in the Robuvit® group. No side effects were reported. CONCLUSIONS CTD, combined with self-management, can effectively control the excess of limb volume in post-mastectomy lymphedema. Supplementation with Robuvit® is useful to further reduce limb volume. Later stages of lymphedema seem to be more difficult to manage and may require surgery or more invasive treatments.
Collapse
Affiliation(s)
- Gianni Belcaro
- IRVINE3 Labs, CH-PE University, Chieti, Italy - .,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy -
| | - Mark Dugall
- IRVINE3 Labs, CH-PE University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Roberto Cotellese
- International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Beatrice Feragalli
- International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Ettore Cianchetti
- IRVINE3 Labs, CH-PE University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| | - Maria R Cesarone
- IRVINE3 Labs, CH-PE University, Chieti, Italy.,International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy
| |
Collapse
|
48
|
Ledda A, Belcaro G, Feragalli B, Hosoi M, Cacchio M, Luzzi R, Dugall M, Cotellese R, Cesarone MR. Temporary kidney dysfunction: Robuvit® supplementation in initial, transient kidney insufficiency and micro-macro albuminuria. Panminerva Med 2018; 60:60-64. [DOI: 10.23736/s0031-0808.18.03420-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
49
|
Feragalli B, Ippolito E, Dugall M, Cacchio M, Belcaro G, Cesarone MR, Abdel-Tawab M, Riva A, Togni S, Eggenhoffner R, Giacomelli L. Effectiveness of a novel boswellic acids delivery form (Casperome®) in the management of grade II ankle sprains due to sport trauma - a registry study. Eur Rev Med Pharmacol Sci 2017; 21:4726-4732. [PMID: 29131239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
OBJECTIVE In this study, we evaluated a novel delivery form of boswellic acids (Casperome®) in the management of signs and symptoms associated with ankle sprain grade II due to sport trauma. PATIENTS AND METHODS In this supplement registry study, 72 otherwise healthy subjects with grade II ankle sprain induced by sport activities were advised to either follow a standard management (SM, 37 subjects) for the condition or the SM with the additional daily intake of 1 tablet containing 250 mg Casperome® (35 subjects). Subjects were allowed to use rescue medications (ketoprofen tablets, 25 mg/tablet), and their intake was measured at the end of the management period of 7 days. Each individual was subjected to several non-invasive examinations (self-reported pain at rest and under moderate exercise, range of active and passive movement, presence of local hematomas by ultrasonography) at the following time periods: at inclusion, to evaluate the basal conditions of the subject before the beginning of the study, at day 3 and at the end of the week to evaluate the response differences between the two groups. Additionally, a blood sample from the Casperome® treated subjects (34 out of 35 subjects) was taken at day 7 and analyzed for the systemic concentration of boswellic acids. RESULTS The 72 individuals recruited in this study spontaneously decided which management to follow, either SM (n=37) or SM+Casperome® (n=35). Supplementation with Casperome® 250 mg/day showed beneficial effects in the reduction of signs and symptoms of ankle sprains evaluated at day 3 and day 7, and was shown to induce measurable plasma level of boswellic acids. Moreover, the supplementary use of Casperome® was well-tolerated and devoid of side effects. CONCLUSIONS Our pilot registry study showed the effectiveness of Casperome® supplementation in improving recovery after ankle sprain of mild severity (grade II), suggesting a potentially beneficial role in relieving the trauma associated with sport activities and in decreasing the use of rescue drugs.
Collapse
Affiliation(s)
- B Feragalli
- IRVINE3 Vascular Lab and Physiology, Chieti - Pescara University.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Belcaro G, Dugall M, Luzzi R, Corsi M, Ledda A, Ricci A, Pellegrini L, Cesarone MR, Hosoi M, Errichi BM, Cornelli U, Cotellese R, Agus G, Feragalli B. Management of Varicose Veins and Chronic Venous Insufficiency in a Comparative Registry with Nine Venoactive Products in Comparison with Stockings. Int J Angiol 2016; 26:170-178. [PMID: 28804235 DOI: 10.1055/s-0036-1597756] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
Abstract
The aim of this registry study was to compare products used to control symptoms of CVI. Endpoints of the study were microcirculation, effects on volume changes, and symptoms (analogue scale). Pycnogenol, venoruton, troxerutin, the complex diosmin-hesperidin, Antistax, Mirtoselect (bilberry), escin, and the combination Venoruton-Pycnogenol (VE-PY) were compared with compressions. No safety or tolerability problems were observed. At inclusion, measurements in the groups were comparable: 1,051 patients completed the registry. Best performers : Venoruton, Pycnogenol, and the combination VE-PY produced the best effects on skin flux. These products and the combination VE-PY better improved PO 2 and PCO 2 . The edema score was decreased more effectively with the combination and with Pycnogenol. Venoruton; Antistax also had good results. Considering volumetry, the best performers were the combination PY-VE and the two single products Venoruton and Pycnogenol. Antistax results for edema were also good. The best improvement in symptoms score were obtained with Pycnogenol and compression. A larger decrease in oxidative stress was observed with Pycnogenol, Venoruton, and with the VE-PY combination. Good effects of Antistax were also observed. Parestesias were lower with Pycnogenol and with Antistax. Considering the need for interventions, the best performers were Pycnogenol, VE-PY, and compression. The efficacy of Pycnogenol and the combination are competitive with stockings that do not have the same tolerability in warmer climates. A larger and more prolonged evaluation is suggested to evaluate cost-efficacy (and non-interference with drugs) of these products in the management of CVI. The registry is in progress; other products are in evaluation.
Collapse
Affiliation(s)
- G Belcaro
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| | - M Dugall
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| | - R Luzzi
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| | - M Corsi
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| | - A Ledda
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| | - A Ricci
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| | - L Pellegrini
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| | - M R Cesarone
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| | - M Hosoi
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| | - B M Errichi
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| | - U Cornelli
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| | - R Cotellese
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| | - G Agus
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| | - B Feragalli
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| |
Collapse
|